<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Avery Bedows on Medium]]></title>
        <description><![CDATA[Stories by Avery Bedows on Medium]]></description>
        <link>https://medium.com/@abedows17?source=rss-c7506c12d100------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*J9L5NwjVy69csM856TfVwQ.jpeg</url>
            <title>Stories by Avery Bedows on Medium</title>
            <link>https://medium.com/@abedows17?source=rss-c7506c12d100------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 10:24:26 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@abedows17/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[On Fiction & Neuralink]]></title>
            <link>https://medium.com/the-substrate/on-fiction-neuralink-ae5fc8a774fe?source=rss-c7506c12d100------2</link>
            <guid isPermaLink="false">https://medium.com/p/ae5fc8a774fe</guid>
            <category><![CDATA[neuroscience]]></category>
            <category><![CDATA[neuralink]]></category>
            <category><![CDATA[neurotechnology]]></category>
            <dc:creator><![CDATA[Avery Bedows]]></dc:creator>
            <pubDate>Mon, 31 Aug 2020 14:17:48 GMT</pubDate>
            <atom:updated>2020-08-31T14:17:48.815Z</atom:updated>
            <content:encoded><![CDATA[<p>But first, a hot take: is it just me, or does Neuralink’s robot sort of look like its logo?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/770/1*NY472Mwqh06GhDBzgQHT4w.png" /></figure><p>Anyhow…</p><p>Originally in the realm of fiction, Neuralink is finally materializing into the real. The company began its public journey as a story: a dream dreamt up by Elon in his Fremont dream factory and chronicled by the fabulously talented <a href="https://waitbutwhy.com/">Tim Urban</a>. Now, the company has real technology with real constraints because, unlike in the world of fiction, degrees of freedom in reality are limited.</p><p>Neuralink was announced through loudspeakers with a ~35,000 word <a href="https://waitbutwhy.com/2017/04/neuralink.html">blog post</a> on <a href="https://waitbutwhy.com/">Wait But Why</a> telling a marvelous story about the imperiled and soon-to-be-saved future of humanity. As the article puts it, artificial intelligence threatens the obsolescence of <em>Homo sapiens</em>, but we can secure our significance and safety by integrating biological intelligence and artificial intelligence. This, it explains, was the vision behind Elon Musk’s new endeavor: a neurotechnology company.</p><p>It wasn’t just the linguistic content. Tim Urban’s distinctive style — of which I’m a big fan — incorporates many cartoons, like the now-infamous brain in a wizard hat. In addition to the distant-future hypotheticals, these cartoons also added to the feeling of fiction, or at the very least of being far-fetched.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*XovM5hAHFwv4ly2M.png" /><figcaption>Brain in a wizard hat. Credits: <a href="https://waitbutwhy.com/2017/04/neuralink.html">Wait But Why</a>.</figcaption></figure><p>Fiction is wonderful. It inspires, it draws up strong emotions, and I would argue it has its own Platonic reality — but it’s also inherently hallucinatory.</p><p>Whereas an inherently fictional endeavor like a film will stay fictional, a real endeavor like a company that begins with fiction must obviously become real in order to succeed. If we look at the three “publicity” data points for Neuralink, we have:</p><p><strong>1) </strong><a href="https://waitbutwhy.com/2017/04/neuralink.html"><strong>Wait But Why</strong></a><strong> article.</strong> <em>Lays out a hypothetical vision of the future and verges into science fiction territory; Neuralink is the ultimate solution to the “problem” of biology.</em></p><p><strong>2) </strong><a href="https://www.youtube.com/watch?v=r-vbh3t7WVI"><strong>Summer 2019 event</strong></a><strong>. </strong><em>Shows off ambitious technology that can be implanted in multiple cortical locations simultaneously. Highlights future applications of novel technology in some detail. Keynote discussion on AI symbiosis &amp; existential threat mitigation (including bandwidth argument), and therapeutic applications are secondary to the storytelling.</em></p><p><strong>3) </strong><a href="https://www.youtube.com/watch?v=DVvmgjBL74w"><strong>Summer 2020 event</strong></a><strong>. </strong><em>Demos a scaled back device. Keynote immediately focuses on therapies. Product sloganeering: Fitbit in your skull with tiny wires.</em></p><p>The progression from the original 2017 article to the Summer 2020 event is distinctly an arc of reification: at each point, the degrees of freedom have reduced (which surely reflects a more continuous degrees of freedom reduction during day to day operations). This isn’t bad; it was inevitable, because any real entity that starts as fiction has to become real, or cease to be. Neuralink is maturing.</p><p>Though perhaps an abstract observation, I think it has real significance for the field. When Neuralink was more fictional, it was like a Schrödinger’s pig: it was and it wasn’t; it could be anything and everything. The towering stature of Elon and the implicit perception of Neuralink as infinite (<em>vis a vis</em> its fiction status) has impacted the investment climate in neurotechnology. Why invest in a brain technology when Elon’s already done it?</p><p>Often, when learning about a field from the outside, (royal) we look for core guideposts to align ourselves to. When Neuralink lived as fiction, its presence could expand to an enormous size and become the predominant aligning guidepost for the neuro-naïve (not meant as a knock on people; myself included, most people are naïve about most things, a fact largely attributable to the size of the set of things). As everyone in neurotechnology knows, the field is much larger than Neuralink. <strong>As Neuralink manifests into the real out of the fictitious, people outside of the field will begin to understand that, too.</strong></p><p>This will play to the advantage of other commercial and academic endeavors in neurotechnology. Neuralink has not developed the panacea of neural interfacing, as neurotech Twitter has been eager to kvetch about. They have (according to neural engineers I trust) done difficult integration engineering, and made a cool demo, and have a tough road forward of technical and clinical validation.</p><p>By becoming real, it becomes clear that Neuralink <em>is</em> certain things (effective systems integrators, adept at design and probably user experience, advancing a product forward) and <em>isn’t</em> (yet?) others (a near-term solution to major depression, vision impairment, neurodegenerative disorders, language decoding, and so on).</p><p>As someone formerly on the venture capital side of things and now on the storytelling &amp; strategy side, my advice is this: use this to your advantage. When an investor asks you about Neuralink, tell the story of its adoption of constraint and focus. You, too, have chosen constraint and focus, and it’s different from Neuralink’s. You have space for your story, and they for theirs.</p><p>To some extent, every business begins a fiction. Some of us start with slides, and some of us start with small books. As reality inevitably takes over and the degrees of freedom shrink, what grows are the specificity and differentiability of the businesses—therein lies competition, and therein lies an industry.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ae5fc8a774fe" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-substrate/on-fiction-neuralink-ae5fc8a774fe">On Fiction &amp; Neuralink</a> was originally published in <a href="https://medium.com/the-substrate">The Substrate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Thoughts on CTRL-Labs]]></title>
            <link>https://medium.com/the-substrate/thoughts-on-ctrl-labs-1dfff4a23799?source=rss-c7506c12d100------2</link>
            <guid isPermaLink="false">https://medium.com/p/1dfff4a23799</guid>
            <category><![CDATA[augmented-reality]]></category>
            <category><![CDATA[neurotechnology]]></category>
            <category><![CDATA[brain]]></category>
            <dc:creator><![CDATA[Avery Bedows]]></dc:creator>
            <pubDate>Tue, 01 Oct 2019 20:29:36 GMT</pubDate>
            <atom:updated>2019-10-01T20:29:36.708Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/984/1*eOu2bE_SoyM4ES8bG-sbfA.png" /></figure><p>While sitting at dinner with an unsuspecting friend, my phone blew up with oddly-late messages from fellow neurotechnology comrades. <a href="https://www.ctrl-labs.com/">CTRL-Labs</a> announced their impending acquisition by Facebook and integration into Facebook Reality Labs (responsible for Oculus et al.), for enough money to buy my guilt-inducingly-expensive New York coffee for a meager 550,000 years. <em>Woah</em> — so very many questions. I figured I’d share (and consider this an open invitation to reach out and throw in your 100 billion cents-worth).</p><p>As a quick note before proceeding, aside from its pragmatic communication implications, I don’t much mind whether or not CTRL-Labs and other EMG technologies hold philosophical credence as true neurotechnologies; what matters is that they’re branded as such. It’s a debate that’s been waged elsewhere, so I’ll leave it be!</p><h3>Q: What does this mean for the neurotechnology field?</h3><h3>Consumer neurotech</h3><ul><li>Consumer neurotechnology has been properly legitimized: there will now be an entry in the technology vernacular for “that neuro company FB bought.” <em>Neurotech</em> will be a true category, and will probably begin to appear on the websites of the more daring venture capital firms. This is non-trivial: when Facebook purchased Oculus in March of 2014, what followed was a huge influx of investments into AR/VR (the successes of which have admittedly been questionable at best). As many VCs are quick to note, VC is a social dance, and billion-dollar surprise exits to a FAANG company is a powerful way to get that game started.</li><li>I’ve spoken to several entrepreneurs in consumer neurotechnology today and, as expected, all of them are excited. This is a win they can point to; a vision they can show might lead to a concrete outcome. It is and will remain motivating for entrepreneurs, their employees, and their present and future investors.</li><li>Even though I don’t personally mind it, this acquisition is going to cause a hassle in nomenclature. To actually understand how CTRL-Labs differs from a central nervous system-BCI requires a bit of basic anatomy/physiology knowledge. For people not in the know (i.e., almost everybody, including most VCs and engineers), this adds an additional layer of complexity/misdirection to how people will think about neuro. Absent detailed information, humans employ underspecified models of semantic domains; that’s what will probably happen in consumer neurotechnology. In the same way, due to my ignorance of quantum computing, any piece of information I learn about quantum computing will apply to the entire field of quantum computing, whereas in reality, it’s just another piece in a complex puzzle. I suspect the same will happen in neuro.</li><li>Control (as opposed to affective computing and the like) is going to be the flagship of neurotechnology, because that’s what <em>CTRL</em>-Labs does. It’s possible that investors, journalists, and technologists will, on average, fall prey to the same underspecified model trap and collapse all “use-cases” into control. (If you want to get a sense for how I create a taxonomy for consumer neurotech, you can skim <a href="https://loupventures.com/consumer-neurotechnology-volume-i/">this</a>).</li></ul><h3>Medical neurotech</h3><p>I’m willing to wager that more of the medical neurotechnology companies I know and will get to know over the coming months are going to emphasize the consumer-crossover angle. “We’re a medical device company now, but we’ll have a patient-facing app which would fit in nicely with the health data focus at [insert your company of choice].” It’s a reasonable notion, and it’s very reasonable for entrepreneurs and investors to be enticed by the idea; who doesn’t like the sound of a $1B pre-revenue acquisition?</p><h3>Venture capital</h3><ul><li>Well, for one, there’s been a large neurotechnology exit now. That’s enticing.</li><li>This is almost certainly going to put neuro onto the radars of generalist VCs and/or specialist VCs who just haven’t specialized in neurotech yet but have plenty of adjacent knowledge in consumer electronics, technically innovative hardware, medical devices, AI of various sorts, etc. This is a good thing, but neurotech founders should think carefully about how to approach the education of non-neuro (read: most) investors. Have primer materials prepared, have current investors on hand willing to help in the educational process, and practice explaining neurotechnology to people in a way that’s impartial and only as informative as your audience wants.</li></ul><h3>Q: What does this acquisition get Facebook?</h3><ul><li>A bunch of talent. A <a href="https://www.ctrl-labs.com/people/"><em>bunch</em></a>.</li><li>I don’t think this acquisition was about neuro; this acquisition was about winning AR/VR. As someone who previously worked on a fairly intricate VR interface, I’d argue the modern missing piece in AR/VR is the ability to have degrees of freedom of control commensurate to what we have over our laptops — i.e., the same DoF of our hands. That’s what Facebook got with this acquisition: the eradication of the barrier between VR and full-depth, intricate applications. To quote a close friend who works in AR/VR, in reference to this acquisition, “It’s an arms race out here” and Facebook just found its new arms in the arms (get it? EMG?).</li></ul><h3>Q: What are the characteristics of EMG use-cases? Pros/cons? Does it obviate the need for head-worn BCIs?</h3><ul><li>In principle, EMG will eventually give your computer access to anything it wants to know about your hands. If we’re constraining ourselves to the physical control mechanisms we’ve evolved to use, then hand kinematics reconstruction is as good as it gets.</li><li>EEG (or other noninvasive modalities), on the other hand, enable interactions we <em>haven’t</em> evolved; whereas as hominids we’ve always used our hands to manipulate things, we have not literally used our brains. The question is whether noninvasive sensing of control signals that don’t cooccur with actual or intended physical motion ultimately leads to as many degrees of freedom as hand manipulation, and what sorts of manipulations are better-suited to abstract control (brain) vs. evolved control (hands/arms).</li><li>EEG is better for motor impairment use-cases because it doesn’t rely on neural signals propagating down the spinal cord.</li><li>We still need central nervous system neurotechnologies to handle cognition and emotion. To appreciate the significance of this, consider the trend (with all its complex positives and negatives) toward understanding the mental states of users in finer-grained detail so that we can adapt technology, and even physical environments, to these states. There are a big class of problems that implicate cognition and emotion, and EMG won’t help us there.</li><li>So, no, CTRL-Labs does not obviate head-worn BCIs!</li></ul><p>These are my initial thoughts. They’ll change and become more detailed over time. Meanwhile, please do reach out and let me know your latest and great perspective — you can find me at “avery at loupventures dot com.”</p><p><a href="https://loupventures.com/research-disclaimer/"><em>Disclaimer</em></a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1dfff4a23799" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-substrate/thoughts-on-ctrl-labs-1dfff4a23799">Thoughts on CTRL-Labs</a> was originally published in <a href="https://medium.com/the-substrate">The Substrate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Neuralink Event: Musings on Messaging]]></title>
            <link>https://medium.com/the-substrate/neuralink-event-musings-on-messaging-61dace55b29f?source=rss-c7506c12d100------2</link>
            <guid isPermaLink="false">https://medium.com/p/61dace55b29f</guid>
            <category><![CDATA[neurotechnology]]></category>
            <category><![CDATA[neuralink]]></category>
            <category><![CDATA[artificial-intelligence]]></category>
            <dc:creator><![CDATA[Avery Bedows]]></dc:creator>
            <pubDate>Tue, 01 Oct 2019 20:27:17 GMT</pubDate>
            <atom:updated>2019-10-01T20:27:17.544Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/900/1*K-4A7_Y93RCsI7My5tzNSA.jpeg" /></figure><p>As anyone who holds at least one ear to the neurotechnology world undoubtedly knows, Elon took the stage on Tuesday night at the California Academy of Sciences to deliver an Elonian exposé on Neuralink’s progress over the last two years. The company’s primary public debut was two years ago, in April, 2017, when Tim Urban released one of his typical <a href="https://waitbutwhy.com/2017/04/neuralink.html">mega-posts</a> on <a href="http://waitbutwhy.com/">waitbutwhy.com</a>, the subject of which was an ostensibly unending and many-part discussion of Neuralink and Elon’s thesis about “the human/AI symbiosis,” or something to that effect. As most people in neurotechnology also likely know, the vision Tim Urban articulated was — as orator for Elon — that of a nearly indistinguishable fusion between biological brains and artificial ones. If humans don’t fuse with AI, the argument goes, then we’ll be overrun by artificially intelligent agents superior to our biological selves in every way. “Elon Musk Fuses Humans with Machines to Save Humanity” — the headlines basically write themselves…</p><p>Which now brings me to a couple of thoughts I want to share on the subject of Neuralink’s messaging, and what we (the neurotechnology-initiated) can learn from it. Many things have been said about Neuralink’s event and technology by many very smart scientists, and I’ve enjoyed and learned from their commentaries; I don’t have much to add on the technical details that hasn’t already been said better than I could say it. To that end, here are some links in case you’re in the market for rabbit holes:</p><ul><li>The <a href="https://youtu.be/r-vbh3t7WVI?t=5461">event</a> itself</li><li>An enjoyable <a href="https://twitter.com/andrewhires/status/1151319583438983168?s=21">Twitter analysis</a> by Andrew Hires</li><li>A <a href="https://www.youtube.com/watch?v=B2-YiXuXdp8&amp;feature=youtu.be">paper reading group</a> at Numenta</li></ul><p>Now, let’s talk about messaging. After the Odesza-soundtracked teaser video of Neuralink’s chic biotech-meets-tech office and its smiling scientists, the first thing Elon shows us is the following slide. In my opinion, this was one of the most interesting things in the presentation, and the speakers were clearly coached to speak along the lines of the framework laid out.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*31aqf5DEgXUfwL9VPBwQFA.png" /></figure><p>Here’s how these read to me:</p><ol><li>There’s no way we can build an invasive brain interface if we’re not going to use it for medical applications first, and many scientists and engineers are probably skeptical of the transhumanist vision, so if we’re going to hire good people, we need to start on planet earth.</li><li>Now, if we do manage to build an implantation procedure that’s extremely easy and safe to perform (their analogy is Lasik surgery), then we can probably start to hint to people that, hey, why not try this out for fun? Do it for yourself — preserve your brain health, and enhance it while you’re at it. Really, it’s the logical next step after eating blueberries for antioxidants and getting eight hours of sleep every night.</li><li>Alright, we can pull out all the stops. Let’s implant everyone and “connect” us all to the internet so we can remain valuable in an AI-ridden future.</li></ol><p>This slide, and indeed the rest of the presentation, contrasts substantially with the messaging in the Wait But Why article. The speakers were all cautious to distinguish between what they’re working on <em>now</em>, and what is futuristic and “aspirational,” to use the word of the evening.</p><p>Neuralink had two paths to go down: the first would have been to ride the hype machine, a la <a href="https://www.magicleap.com/">Magic Leap</a>, putting out mysterious marketing and keeping internal work secretive. The second option was to open up the science and tone down the marketing. They chose option two, and they pretty much explicitly said they did it for hiring purposes. I can’t be sure, but I suspect they hosted the event <em>reactively</em> to issues with hiring, rather than proactively. If indeed they hosted the event as a reaction, I’d be curious to know what the issues were, and whether or not they were a function of Neuralink’s previous flavor of mystery and secrecy.</p><p>As an additional musing, I think Neuralink did something positive for neurotechnology by bringing their branding down to earth. Understanding neurotechnology requires substantial background information: neuroscience, various engineering disciplines, medicine, regulation, etc. Most people in the general public have few or none of those topics in their toolbox, which means that neurotechnology is easier to understand in terms of sweeping generalizations. Compare this with Musk’s other companies: Tesla is making electric vehicles. SpaceX is sending people to Mars. The Boring Company is building tunnels for transportation. Neuralink is connecting humans to AI. Of the four one-line descriptions, the one that requires the most nuanced interpretation is undoubtedly Neuralink’s. Had Neuralink continued their public-facing transhumanist reductionism of neurotechnology, I would have worried that the general public and non-scientist governmental regulators would have begun to view neurotechnology as a wrecking ball, even more than some already do. Instead, though, Neuralink has primed the public and the media to appreciate how ridiculously complicated it is to develop neural interfaces, and how slow-going it will be. That should bode well in a climate of technology scrutiny.</p><p>As a proud owner of a shirt bearing the infamous <a href="https://images.app.goo.gl/24kAFVTnTS6mj6k4A">wizard hat-wearing brain</a>, it was gratifying to finally see an update from the company that undergirds much of the public interest in neurotechnology.</p><p><a href="https://loupventures.com/research-disclaimer/"><em>Disclaimer</em></a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=61dace55b29f" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-substrate/neuralink-event-musings-on-messaging-61dace55b29f">Neuralink Event: Musings on Messaging</a> was originally published in <a href="https://medium.com/the-substrate">The Substrate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Story of Rune Labs]]></title>
            <link>https://medium.com/the-substrate/the-story-of-rune-labs-47fddf1c9419?source=rss-c7506c12d100------2</link>
            <guid isPermaLink="false">https://medium.com/p/47fddf1c9419</guid>
            <category><![CDATA[neurotechnology]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[neuroscience]]></category>
            <dc:creator><![CDATA[Avery Bedows]]></dc:creator>
            <pubDate>Tue, 01 Oct 2019 20:24:14 GMT</pubDate>
            <atom:updated>2019-10-01T20:24:14.536Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*f_1H8Fgk8LltTZqgVPtZ3w.png" /></figure><h3>The Story of Rune Labs</h3><p>The nervous system is the substrate of human experience. Logic would therefore predict, and experience would confirm, that some of the most phenomenologically pernicious diseases and disorders are those that implicate the nervous system. This specific insight is the motivation behind our commitment to <a href="https://loupventures.com/category/themes/neurotech/">neurotechnology</a> at Loup, and it’s within this context that I’m extremely excited to share publicly our newest neurotechnology investment: <a href="https://runelabs.io/">Rune Labs</a>!</p><p>Rune, under the direction of CEO Brian Pepin, is developing a software platform for brain data.</p><h3>Laying out some context</h3><p>If there’s one high-level trend I’ve identified in neuroscience and neurotechnology — via literature and via conversation–it’s that circuits are in vogue. The central and peripheral nervous systems are structures of dumbfounding complexity and faced with dumbfounding complexity, the classic human recourse is to abstract, abstract, abstract until we’ve reached a level of granularity that lends itself to comprehensible analysis and scientific investigation. A brain can be investigated at the level of a molecule, such as when studying the structure of a membrane protein. A brain can be investigated at the level of statistical characterization of a large and stochastically-interacting set of molecules, such as when studying ion fluxes and action potentials. A brain can be investigated at the level of microbiology, such as when studying cell migration during neural development. And, lastly and importantly, a brain can be investigated at the level of neural circuits. It’s this last level of abstraction that’s seen strong uptake in recent years, in both research and translational settings.</p><p>The neurocircuitry level of abstraction is prominent in basic science, but it also shows its face in clinical research: in the translational setting, the neurocircuitry view has yielded the field of neuromodulation. Neuromodulation is by no means new, but it’s growing in size and <a href="https://loupventures.com/neuralink-event-musings-on-messaging/">publicity</a>. A non-exhaustive list of modulation technologies that leverage the circuitry approach includes <a href="https://www.sciencedirect.com/science/article/pii/S0149763405000199">vagus nerve stimulation</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0014488609001290">transcranial direct/alternating current stimulation</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0149763417304840">transcranial magnetic stimulation</a>, and <a href="https://jamanetwork.com/journals/jamaneurology/article-abstract/802237">deep brain stimulation</a> (DBS). Here, we’ll focus on DBS. DBS has FDA approval for use in Parkinson’s Disease (PD), and to date, more than <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397644/">160,000 patients</a> have been implanted for PD and other indications. “Other indications” refers to the investigative work happening in, for example, treatment-resistant major depressive disorder, treatment-resistant obsessive-compulsive disorder, and addiction disorders (among others).</p><p>Original DBS devices — i.e., most of the devices currently implanted in commercial settings — only have the capability to stimulate the brain. This makes it challenging to customize therapy to individual patients, and impossible to design therapies that use realtime information about circuit activity to determine when/how to stimulate. A new wave of devices is under development that can both record <em>and </em>stimulate; these are referred to as “closed-loop” DBS devices.</p><h3>Confluence of problems</h3><p>Brian founded Rune to solve a confluence of problems. At the most abstract level, brain disease is complex because brains are complex; this means that any data recorded from the brain will be hard to analyze. Furthermore, in the domain of psychiatric disorders wherein the disorders are characterized largely by their qualitative, phenomenological symptomatology, there’s the added challenge of finding ways to measure phenomenological states — which is arguably impossible in a philosophical sense.</p><p>There are also more concrete problems facing the treatment of neurological and psychiatric disorders via neurotechnologies such as DBS.</p><ul><li><strong>Noise</strong>. Any brain measurements, whether electrical or otherwise, will contain some degree of noise. Neurophysiological data is notoriously noisy, meaning certain recording segments can’t be used since they’ll skew analyses.</li><li><strong>Longitudinality</strong>. PD, TRD, etc. all progress and/or fluctuate over long periods of time. PD, for example, is known to have a circadian fluctuation, which is notoriously difficult to capture through discrete clinical visits. Tracking these diseases/disorders must therefore require researchers to capture data over a long time span; this impacts clinical trial design, algorithm/treatment development, and therapy delivery in commercially-implanted patients. In addition to the idea of longitudinality having paradigmatic significance, there are practical concerns: large data sets are hard to work with. Some things that can contribute to the size of electrophysiological data are, for example, the number of recording channels, the sampling rate, and the duration of the recording. Closed-loop DBS, in particular, will create longitudinal electrophysiological recordings that haven’t existed before: with <a href="https://commonfund.nih.gov/sites/default/files/Medtronic%20v3_508.pdf">RC+S</a> being implanted and the Percept trial on the horizon, there is likely to be more invasive human neural data collected in 2020 than every previous year in history combined.</li><li><strong>Patient environment</strong>. The patient’s environment interacts with brain disease, and therefore environmental factors have to be considered and possibly tracked when developing and delivering therapies.</li><li><strong>Patient experience</strong>. If neural data comprises “measurements,” such as the data recorded by a closed-loop DBS system, then in order for a supervised learning algorithm to know how to respond to the measurements, it must decide how those measurements relate to positive patient experience vs. negative patient experience. This amounts to collecting labeled neural data from patients, and infrastructure to do so is generally poor.</li><li><strong>Complex feature spaces. </strong>Given a time series of neural data (or any other kind of neural data), there are many possible ways to transform that data to derive useful “features” for use by a learning or control algorithm. Handling large feature spaces, as well as selecting high-performing features, requires time (and therefore money) as well as computational power.</li></ul><p>Each of these categories can and do fill books. The conclusion, though, is simple: treatment of neurological and psychiatric disorders has miles and miles of road left to build and travel, and many of these miles will be paved by data.</p><p>Time series neural data (electrophysiology and/or fMRI) is so dense and complex that it isn’t human-readable. Furthermore, any model we have that goes beyond more than a few neurons interacting is necessarily a massive simplification and surely throws out many mechanisms. Brian believes these factors motivate the need to use modern deep learning approaches to understand the data and generate new insights. However, to pull this off requires a lot of data that is harmonized at some level by similar labels, sampling characteristics, etc. Data is siloed right now, sometimes even at the level of a single patient clinical visit, preventing harmonization — and that is where Rune comes in: Rune provides unified software interfaces to a large number of patients, researchers, and clinicians that solve the issues outlined above and allow the aggregation of datasets amenable to AI.</p><h3>Rune’s solution</h3><p>Rune is developing a software platform for the labeling, ingestion, cleaning, visualization, and analysis of intracranial brain data. In the technology world, data has scaled, and therefore so has the intricacy of the software engineering necessary to derive value from the data. Brian and his team are bringing the same strategy to neurotechnology.</p><p>In conjunction with a researcher-facing platform, Rune has launched a <a href="https://strive.group/">patient-facing application</a> for Parkinson’s patients to track symptoms; this data is fused with neural recordings on the backend to give physicians and researchers better insight.</p><p>Rune’s software platform moves the needle on the problems we discussed above:</p><ul><li><strong>Noise</strong>. Rune’s software automatically removes chunks of data that are too noisy to use.</li><li><strong>Longitudinality</strong>. The Rune platform is being engineered to handle longitudinal data efficiently; this will expedite R&amp;D of therapies that incorporate longitudinal changes/trends in patient behavior and neural data.</li><li><strong>Patient environment</strong>. Through the patient app, Rune can collect and supports the analysis of data corresponding to environmental variables of interest.</li><li><strong>Patient experience</strong>. The patient-facing application is designed from the ground up to capture patients’ experience with their conditions and to use that data to understand the impact of neurotechnological interventions.</li><li><strong>Complex feature spaces</strong>. Rune has various efficiently-implemented data transformations and visualizations built into the platform, enabling researchers to quickly investigate data and test hypotheses.</li></ul><h3>Where they are and where they’re going</h3><h4>Near-term</h4><p>Today, Rune launched their patient-facing app for PD patients, called <a href="https://strive.group/">Strive PD</a>. The app was designed by people with Parkinson’s, for people with Parkinson’s. It serves as a patient portal to information about their therapy and lets patients record relevant information such as their symptoms and whether or not they took their medication. If patients want, they can share the data with clinicians and caregivers to help find the right mix of therapy. In the context of new therapy development, Rune can adapt its baseline patient app to support new use-cases, including direct wireless connection to implanted devices.</p><p>Rune is also actively partnering with global leaders in the development of DBS therapies. Initially, they’re focusing on accelerating development of improved DBS therapies for Parkinson’s, and as time goes on they’ll expand to other indications.</p><h4>Long-term</h4><p>As with most things in our world these days, the more patients we help, the more patients we can help; in other words, we use the data from present patients to help future patients, and this cycle compounds exponentially as the datasets grow. It seems likely that psychiatric and neurological healthcare continue on their data-centric trajectories, which means there will be a tension between the convenience of non-invasive and/or proxy data — such as data collected from wearables, smartphones, and ambient sensors — and the “closeness to the source” of intracranial brain data. Rune’s long-term vision is to expedite and validate the development and commercialization of new neurological and psychiatric therapies by partnering with other researchers and businesses: as therapies get more complex and personalized, the primary innovation will be in the development of new software and algorithms — right at the nexus of Rune’s expertise.</p><h3>Conclusion</h3><p>If one thing is certain about the direction of brain science, it’s that the quantity and precision of data we have about the brain is only going to increase. Therefore, there is a strong need to leverage that data to develop therapies, and we’re thrilled to be working with Brian and his team at Rune to do just that.</p><p><a href="https://loupventures.com/research-disclaimer/"><em>Disclaimer</em></a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=47fddf1c9419" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-substrate/the-story-of-rune-labs-47fddf1c9419">The Story of Rune Labs</a> was originally published in <a href="https://medium.com/the-substrate">The Substrate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How to insert a neural implant like you floss your teeth]]></title>
            <link>https://medium.com/the-substrate/using-a-teeth-flossing-life-hack-to-insert-a-neural-implant-aea20d476631?source=rss-c7506c12d100------2</link>
            <guid isPermaLink="false">https://medium.com/p/aea20d476631</guid>
            <category><![CDATA[software-development]]></category>
            <category><![CDATA[brain]]></category>
            <category><![CDATA[neurotechnology]]></category>
            <category><![CDATA[medical-devices]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Avery Bedows]]></dc:creator>
            <pubDate>Wed, 04 Apr 2018 19:43:51 GMT</pubDate>
            <atom:updated>2018-04-08T09:14:52.145Z</atom:updated>
            <content:encoded><![CDATA[<p>In this episode of the Neural Implant Podcast, Ladan interviews Dr. Ryan Clement about his work on a mechanism to make it <em>much</em> easier to insert neural implants. The trick? Move the implants back and forth very quickly, just like floss!</p><p><strong>Tl;dr: In this post, I’ll walk through Ladan’s discussion with Dr. Clement about NeuralGlider, a device that helps researchers insert neural implants without damaging brain tissue. Then, I’ll discuss the development of medical products like NeuralGlider and how the development process is impacted by regulation. Finally, I’ll let my thoughts wander to the regulation of software products.</strong></p><h3>The Episode</h3><p>Dr. Ryan Clement is the pre-clinical studies leader at <a href="http://www.actuatedmedical.com/">Actuated Medical</a>, a company that develops medical devices relying on ultrasonic vibration technology. According to their <a href="http://www.actuatedmedical.com/leadership.html">website</a>, “Ryan directs our testing program ensuring it is verified, validated, and generates the scientific data required for regulatory clearance.” Simple enough!</p><p>Actuated Medical doesn’t only develop devices that fall within one particular domain or use-case; rather, they take underlying expertise in ultrasonic technology and look for use-cases where ultrasonic technology is uniquely useful. In the past, they’ve made devices such as TubeClear, which can clean clogged feeding tubes through vibration. NeuralGlider, in contrast, applies ultrasonic technology to brain implants.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*uSITlHEj2oX8kH404Hr18w.png" /><figcaption>Image: <a href="http://neuralglider.com/">NeuralGlider</a>. This is an image of the NeuralGlider insertion device.</figcaption></figure><p>Let’s talk about the NeuralGlider device! The patent for NG can be found <a href="https://patents.google.com/patent/US9220483B2/en">here</a>, in case you feel like getting mired in dense legopatentalese (just coined it; “legal patent language”). The idea is as follows:</p><p>When electrode arrays are implanted, they can dimple the brain tissue. This is undesirable because this dimpling damages tissue and can reduce the quality of electrode recordings, either due to biological reaction or due to damage to the probes (electrodes) themselves. The nature of the dimpling effect is that when you pack more electrodes tightly together, the dimpling becomes worse.</p><p>Let’s build some intuition for this. Suppose you’re on a trampoline, and because you’re a phenomenal gymnast, you can do a one-armed handstand. When you’re in your one-armed handstand, the trampoline deforms downwards significantly; the pressure applied is high (large force, distributed across the small surface area of your hand). Now, suppose you put all four limbs on the trampoline: there will be a dimple around each hand and foot, but the dimple will be much less deep than when you were doing your magnificent one-armed hand-stand. This is because the force is distributed across all four limbs, so the pressure applied by each limb is smaller than when you were doing a one-armed handstand.</p><p>In the case of a trampoline, where you <em>really</em> want the trampoline to stay intact, this is perfect. Distribute the force! But, neural implants are another story altogether. The electrodes need to poke through the pia, the layer surrounding the cortex. If you insert one electrode, it applies force to a small surface area, therefore making it easy(ish) to rupture the pia and insert the electrode into cortical neurons. However, if you have a whole array of electrodes (equivalent to a whole lot of hands and feet pressing into the trampoline), each individual electrode/hand/foot is applying very little force to the pia…and therefore, in order to actually penetrate the pia, you need to displace the tissue further (therefore applying more force). In other words, you’re on all fours on the trampoline, and you need to get a friend to sit on your back.</p><p>According to Dr. Clement, researchers have tried a couple of solutions. The first is to use pneumatic insertion, as in the case of the <a href="https://medium.com/the-substrate/paralysis-is-no-match-for-guitar-hero-e03d5efcac82">Utah Array</a>. Essentially, a pneumatic cannon launches the array into the cortex; the velocity helps the electrodes poke through the pia without deforming the brain tissue.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/776/1*cG3XsT9WHzwNEugwnu7kvw.png" /><figcaption>Image: <a href="https://link.springer.com/article/10.1007%2FBF02368133">Rousche and Normann, 1992</a>; a schematic for a pneumatic inserter.</figcaption></figure><p>Another option is to insert the electrodes very slowly, and hope that this will give the tissue time to stretch out and become easier to poke through. Still, Dr. Clement says, researchers might have to push the electrodes in 50% further than originally intended in order for the “brain to pop” (his words).</p><p>Actuated Medical’s solution is to rapidly vibrate the electrode array, making it easier to insert. You might be able to gain some intuition for this by thinking about flossing. Trying to nudge static floss between tightly-packed molars is extremely difficult; but, if you jiggle the floss, it becomes easier. Why is this the case? In physics, kinetic friction is lower than static friction (kinetic = the friction-receiving object is moving; static = the friction-receiving object is stationary). The moving floss experiences kinetic friction, whereas the still floss experiences static friction. In a similar manner, a vibrating electrode array experiences <em>kinetic</em> friction against the brain tissue instead of static friction, and therefore it’s easier to penetrate the pia.</p><p>Don’t believe me! Believe the data:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*iBqPFICb3tKO_UQHWtfwNQ.png" /><figcaption>Image: <a href="http://neuralglider.com/">NeuralGlider</a>; “Actuated” means the implant was inserted using ultrasonic vibration; “Un-Actuated” means the implant was inserted normally. In these parallel images, it’s easy to see how much less Actuated insertion deforms the tissue than Un-Actuated insertion.</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/987/1*sneV-BY9SJ5PPzHE3OJTfQ.png" /><figcaption>Image: <a href="http://neuralglider.com/">NeuralGlider</a>; “Agar” is a gelatinous model for brain tissue; “Rat” means a rat brain was used; “Porcine” means a pig brain was used. In these graphs, the y-axis shows the percentage of the Control. So, the gray bars (which display Control data) all have height y = 1 (100%). The orange bars, then, show what percentage of the Control force/surface displacement the Vibrated electrodes cause. The orange bars are very short relative to the gray bars; this system works pretty well!</figcaption></figure><h3>Rumination</h3><p>The introduction of neural interfaces into therapeutic and eventually enhancement settings will be a long process. One interest of mine is looking at the dynamics of the BMI/bioelectronic medicine world from a high level, and eventually using that knowledge to help craft ethical and effective paths forward. As such, it’s important to understand the neural implant development cycle at all levels of abstraction. Here, we’ll study the level of an individual product developed by an individual company, based on some great information on Actuated Medical’s website.</p><p>Actuated Medical is a medical device company, and developing medical devices is obviously different from developing e.g. software products (which is the realm of technological product development with which I’m the most familiar). Let’s first build an understanding of what Actuated Medical’s particular medical device development cycle looks like, and then we can compare that to software development. To do so, we’ll use a case study from another one of Actuated Medical’s products, called TubeClear. <a href="http://www.actuatedmedical.com/tubeclear-system.html">TubeClear</a> is a device that can clear a clogged <a href="https://en.wikipedia.org/wiki/Feeding_tube">feeding tube</a>—a feeding tube is used to deliver nutrients to a patient who can’t eat due to their condition or treatment. (No, this isn’t a neural implant — but, it <em>is </em>a medical device, and therefore subject to similar considerations and regulations, so I think it’s a reasonable proxy for discussing neural implant development.)</p><p>Actuated Medical’s website specifies their particular <a href="http://actuatedmedical.com/grants-to-fund-development-successes.html">seven-step process of developing products</a> (the following words are quoted directly, but the list formatting is my own addition in order to improve readability):</p><blockquote>1. Clinical need was understood</blockquote><blockquote>2. State of practice was identified</blockquote><blockquote>3. Clinical consultants were selected</blockquote><blockquote>4. Proposal was written and submitted in December 2007, resulting in a Phase I Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF) — awarded in July 2008</blockquote><blockquote>5. During Phase I, our device was investigated (Stage 1) and proven feasible (Stage 2)</blockquote><blockquote>6. We submitted a Phase II SBIR grant proposal in December 2008, which was awarded in July 2009</blockquote><blockquote>7. The device was developed from concept to verification-and-validation testing (Stages 4 &amp; 5), and a 510(k) application for market clearance was submitted to the FDA June 2011</blockquote><p>Here, the “Stages” refer to Stages of Actuated Medical’s development cycle. We can also take a look at a visualization of their product cycle, found on their website:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*vxAMRIPQdouJyu3tDkYdQg.png" /><figcaption>Image: <a href="http://actuatedmedical.com/approach.html">http://actuatedmedical.com/approach.html</a>.</figcaption></figure><p>(A quick note: the FDA website <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K123659">says</a> that TubeClear was given approval in December 2012.)</p><p>Let’s dissect some of the similarities/differences between this product development pathway and the product development pathways you see at technology companies.</p><h4>Need-finding: same!</h4><p>No matter what product you’re developing, you need to first identify a need for that product. Otherwise, no one will buy it. If you ever find yourself living in Silicon Valley, you’ll hear this over and over and over…and over again, probably to the point of sigh-inducing banality.</p><h4>Identifying the state of practice: similar, but there are differences</h4><p>I’m not privy to the details of Actuated Medical’s state-of-practice-identification process, but the idea seems rather self-explanatory: figure out what solutions are currently used to e.g. clean clogged feeding tubes, and determine whether or not a better solution is desirable/imaginable.</p><p>The analogue in technology development is performing competitor research and understanding solutions offered by competitors (for example, if you’re building Dropbox, you would likely want to research Google Drive and figure out what its strengths and weaknesses are). Although I’ve never been part of a medical device’s development, I’m imagining that “practice” for medical devices doesn’t just entail “what does that piece of software do?” It probably implicates: insurance, regulation, materials, medical risk, cost, training practitioners to use the device, maintenance/upkeep…etc. In other words, I think it’s probably a more complex task to understand the current state of practice for a particular medical use-case than it is for a particular software use-case.</p><h4>Grant funding: different!</h4><p>This is a major difference between most software technology and medical technology businesses: MedTech business can apply for grant funding from the government. Unlike venture capital or other forms of investment, this grant funding <strong>a)</strong> is non-dilutive (which means the investor doesn’t gain ownership over some portion of the company), and <strong>b)</strong> doesn’t need to be paid back. Actuated Medical, in particular, pursues <a href="https://en.wikipedia.org/wiki/Small_Business_Innovation_Research">Small Business Innovation Research (SBIR) grants</a>.</p><h4>A quick aside on SBIRs</h4><p>SBIR grants are government-given grants targeted at for-profit businesses with fewer than 500 employees. Each year, $2.5bn in grants are awarded through the three-phase SBIR program.</p><p>In <strong>Phase I</strong>, companies are awarded up to $150k for six months of exploring the technical merit/feasibility of any idea.</p><p>In <strong>Phase II</strong>, companies are awarded $1M for up to two years to explore commercialization, assuming positive results from Phase I.</p><p>In <strong>Phase III</strong>, no additional funding is given; this is when the business takes the product to market and must rely on other funding sources (such as debt or venture capital).</p><p>One large benefit of the SBIR program is that the companies own their IP (intellectual property) and commercialization rights to the technology they develop with grant funding; as such, some well-known and extremely successful companies obtained SBIR grants in their early days. <a href="https://www.nsf.gov/oig/outreach/sbirworkshop/SBIR%20IG%20Presentation%205-5-16%20(Williams).pdf">Examples</a> are <a href="http://symantec.com/">Symantec</a> (cyber security), <a href="http://qualcomm.com/">Qualcomm</a> (semiconductors and telecom), <a href="http://www.davincisurgery.com/">Da Vinci Surgical Systems</a> (robots for performing minimally invasive surgery), and <a href="https://jawbone.com/">Jawbone</a> (fitness trackers).</p><h4>Market clearance: different!</h4><p>“Market clearance” means that the FDA has given a company the thumbs-up to actually sell their product. This is another enormous difference between MedTech and software technology. Non-regulated software technology can launch whenever…this was the case for my previous company, <a href="http://altarvirtual.com/">Altar</a>. (Note: some software technology is regulated, such as software that works with <a href="https://en.wikipedia.org/wiki/Health_Insurance_Portability_and_Accountability_Act">health care records</a>, or software that deals with financial transactions).</p><p>In contrast, medical device regulation is extremely complicated, and people make entire careers out of consulting with companies who are trying to navigate the FDA’s regulatory process. To give you the tip of the convoluted iceberg:</p><h4>A quick aside on medical device regulation</h4><p>There are three federally-specified classes of device: Class I, II, and III. Class I devices are the least regulated, and Class III are the most regulated.</p><p>When developing a <strong>Class I</strong> or <strong>Class II</strong> device, a business is required to tell the FDA before it starts marketing and selling the device. This is known as a <a href="https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification510k/default.htm"><strong>510(k) premarket notification</strong></a>. As part of the application process, the company must prove that their device works similarly, is similarly safe, and is similarly effective to another device which was already given the thumbs-up under 510(k). This is known as “<strong>substantial equivalence</strong>.”</p><p>If a device fails to obtain 510(k) approval because the device isn’t substantially equivalent to another device which came before it, then the company can make a <strong>De Novo</strong> submission and request their new device to be classified as Class I or Class II (Class I &amp; II devices are devices that obviously need to function correctly and be safe, but which aren’t directly sustaining or supporting human life). If the device <em>does</em> directly sustain/support human life then the company must make a <strong>Premarket Approval Application (PMA)</strong> for the device to be classified as Class III. PMAs are the most stringent premarket review process specified by the FDA.</p><p>In general, navigating the FDA regulatory process is extremely complicated, and requires years, millions of dollars, and trained consultants. This is the biggest difference between medical technology development and unregulated software technology development.</p><h3>Pivoting the Rumination to a Different Topic</h3><p>While writing this, I couldn’t help but wonder what regulation might look like for consumer-facing software applications. So, here we go…</p><p>I think there could be two broad categories of regulation: data privacy and user health. There’s certainly discussion in the public forum around the former, and it’s reached a peak lately due to the Cambridge Analytica/Facebook <a href="https://www.nytimes.com/2018/03/19/technology/facebook-cambridge-analytica-explained.html">fiasco</a>. The demand for this regulation is high, and the difficulty of implementation is manageable (c.f. <a href="http://www.onlinetech.com/resources/references/what-is-hipaa-compliance">HIPAA</a>, a piece of legislation designed to protect the privacy of digital health data).</p><p>More thorny and amorphous is user health, or in other words psychological impact. It’s undeniable that consumer-facing software technology can have negative psychological outcomes; this is particularly true of social media. The intuition can be found in the compulsion some (*raises hand*) feel to check their (*my*) phones. We seek recurring rewards: every time I open Facebook, I’m hoping for a red notification symbol, and when it’s there I feel the same as while I’m anticipating it. If there’s no notification, I feel a little hammer chipping away at my soul (and my dopaminergic neurons probably decrease their firing rates significantly). An interesting life-hack I recently came across is (if you have an iPhone) to <a href="https://lifehacker.com/change-your-screen-to-grayscale-to-combat-phone-addicti-1795821843">switch your phone into black/white mode</a>. Give it a try, tell me what you think…</p><p>There’s also science here, but it unfortunately hasn’t entirely converged. There have been conflicting results, but studies like <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743827/?tool=pmcentrez">this</a> and <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853817/">this</a> are reporting negative associations between Facebook usage and well-being. <a href="http://www.mdpi.com/1660-4601/8/9/3528/htm?hc_location=ufi">This paper</a> reviews the psychology literature on social media and addiction.</p><p>When a consumer-facing technology product is nascent and has very few users, I would argue that user-health-focused regulation is irrelevant. But, when a product has a usage magnitude on the order of millions or billions (echem, Facebook), then it’s time to start talking about the health of users. The notion of well-being-focused regulation is…difficult. There’s huge variability in how people respond to technology platforms (my evidence for this is anecdotal, but my anecdotal sample size is roughly the size of my real-life social network). Furthermore, the line between “this person isn’t exercising the willpower to not overuse technology” and “this technology has caused this person to become addicted to it” is extremely fine, mired in free will, and generally finds itself tiled with very sharp conversational thorns.</p><p>I’m proposing the following regulatory framework not because I’m for or against it, but for the sake of a thought experiment regarding the human impact of technology. Here we go:</p><h4>A proposed software regulation paradigm</h4><p>Not everyone who uses a given piece of software (let’s say, Facebook) will become addicted or experience a large amount of negativity due to using it. Let’s say that <strong><em>Y</em></strong>% of all people are <a href="https://link.springer.com/article/10.1007/s11469-018-9871-2">susceptible</a> to this negativity, and we decide that if more than <strong><em>Z</em></strong> people using a given platform are susceptible to negativity, then we ought to do something about it. We can use this to calculate a “<strong>threshold of alarm</strong>,” denoted <strong><em>T</em></strong>. This is calculated: <strong><em>T</em></strong> = <strong><em>Z</em></strong> / (<strong><em>Y</em></strong> / 100) = 100<strong><em>Z</em></strong> / <strong><em>Y</em></strong>. If we decide that no more than <strong><em>Z</em></strong> = 500 users can be susceptible, and <strong><em>Y</em></strong> = 4% of people are susceptible to this given platform, then our threshold is <strong><em>T</em></strong> = 500 * 100 / 4 = 12,500 users.</p><p>(For the sake of this thought experiment, I’ll gloss over the problem that I think is most immediate and deathly glaring: how on <em>earth</em> do you find a reasonable susceptibility metric for <em>every consumer software product on the market</em>?)</p><p>When a software product launches, assuming its <strong>susceptibility factor</strong> (= <strong><em>Y</em></strong> / 100) is known, it wouldn’t yet need to be regulated. This would allow the classic speedy and iterative development paradigm Silicon Valley holds so near and dear to its (Silicon?) heart. However, upon surpassing the threshold of alarm (<strong><em>T</em></strong>), the company could be required to enter into a software-focused version of “clinical” trials, where:</p><ol><li>The positive values of the software product are clearly articulated and tested according to the level of rigor held as standard in academic psychology or neuroscience circles; in essence, the question of “is the reward worth the risk?” is asked.</li><li>“Side effects” (i.e., negative psychological or physiological effects like heightened blood pressure) are characterized.</li><li>If the results of the previous two inquiries aren’t up to some standard of operation, then the company would be required to modify the product over some time period in order to continue growing the user-base. The goal of product modification would be to lower the susceptibility factor and maximize the positive value of the product.</li><li>Even without offering any detail on implementation, those previous three points sound marvelously tedious. So, this sort of regulation would place pressure on a company, from Day 1 onwards, to build products that have clearly articulated human impact value, in addition to the requisite economic value. This is the most important part of the hypothetical regulation, in my opinion: biasing companies towards being conscientious of their human impact.</li></ol><p>Although just a thought experiment where I egregiously gloss over details, I think this is nonetheless worth proposing. In case I failed to make it apparent through my writing, this line of thought derives from my philosophy that technology has to be designed to improve the human experience, and minimize unintentional fallout from doing so.</p><h3>In Conclusion</h3><p>In this post, we discussed the ultrasonic neural implant insertion apparatus pioneered by Actuated Medical, called NeuralGlider. We then studied Actuated Medical’s case study of their own product development process, and compared medical device development with software development. Finally, we wandered down thought experiment lane in an effort to imagine what regulation of consumer-facing software technology might look like.</p><p>One of my primary goals with The Substrate is to encourage an ethics-first conversation about brain computer interfaces. To that end: comment, write me at <a href="/service/mailto:hello@thesubstrate.com">hello@thesubstrate.com</a>, or find me on twitter (@averybedows). I will respond! (seriously, I will).</p><p>Until next time,</p><p>Avery</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=aea20d476631" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-substrate/using-a-teeth-flossing-life-hack-to-insert-a-neural-implant-aea20d476631">How to insert a neural implant like you floss your teeth</a> was originally published in <a href="https://medium.com/the-substrate">The Substrate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[When a nerve can be your glucometer]]></title>
            <link>https://medium.com/the-substrate/when-a-nerve-can-be-your-glucometer-3a198e4da4f3?source=rss-c7506c12d100------2</link>
            <guid isPermaLink="false">https://medium.com/p/3a198e4da4f3</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[cognitive-science]]></category>
            <category><![CDATA[brain]]></category>
            <category><![CDATA[neurotechnology]]></category>
            <category><![CDATA[inflammation]]></category>
            <dc:creator><![CDATA[Avery Bedows]]></dc:creator>
            <pubDate>Tue, 13 Mar 2018 23:33:07 GMT</pubDate>
            <atom:updated>2018-03-14T01:56:52.534Z</atom:updated>
            <content:encoded><![CDATA[<p>When Ladan Jiracek of the Neural Implant Podcast saw <a href="https://sites.google.com/site/theozanos/">Dr. Theodoros Zanos</a>’s poster at SfN 2017, Ladan was so excited that he sought out Dr. Zanos to interview him.</p><p>What compelled Ladan so much? Dr. Zanos has figured out how to listen to the vagus nerve, probably the largest and most prolific nerve in the body, and hear the messages it’s sending to the brain.</p><p>In <a href="http://neuralimplantpodcast.com/dr-theodoros-zanos-on-reading-insulin-and-glucose-levels-from-the-vagus-nerve">this episode</a> of the Neural Implant Podcast, Dr. Zanos discusses how he teases out the body’s internal signals as they’re being sent from the body, through the vagus nerve, to the brain.</p><p><strong>Tl;dr: In this post, I’ll discuss Ladan’s interview with Dr. Theo Zanos, I’ll explore a study about using vagus nerve stimulation to treat inflammatory disease, and I’ll do my very darnedest to get you excited about bioelectronic medicine (but I’ll only scratch the surface of what bioelectronic medicine is, and what it’s all about).</strong></p><h3>The Episode</h3><p>Dr. Zanos is the head of the Neural Decoding and Data Analytics lab at the Feinstein Institute’s <a href="https://www.feinsteininstitute.org/programs-researchers/bioelectronic-medicine/">Center of Bioelectronic Medicine</a>. Zanos has been working on intercepting the peripheral nervous system’s communication with the brain in order to diagnose and fight disease — his recent work focuses on decoding signals from the vagus nerve such as how much glucose is in your blood stream. He and Ladan met at SfN 2017, where Zanos’s poster absolutely blew Ladan away.</p><p>Dr. Zanos begins his interview with Ladan by recounting his lab’s two main findings from this year, both of which pertain to decoding information from the body as it’s sending signals back to the brain. Zanos’s group figured out how to decode information about cytokines, and how to decode information about <strong>insulin</strong> and <strong>glucose</strong> levels, just from recording the <strong>vagus nerve</strong> of a rodent under anesthesia. <em>[A note: </em><strong><em>cytokines</em></strong><em> are small proteins which mediate inflammatory response. For example, </em><a href="https://en.wikipedia.org/wiki/Tumor_necrosis_factor_alpha"><strong><em>TNFα</em></strong></a><em> </em><strong><em>(Tumor Necrosis Factor alpha)</em></strong><em> is a cytokine which activates </em><a href="https://en.wikipedia.org/wiki/NF-%CE%BAB"><strong><em>NF-κB</em></strong></a><em> </em><strong><em>(nuclear factor kappa-light-chain-enhancer of activated B cells)</em></strong><em> (oh my goodness was that a mouthful), which is itself a gene transcription factor that impacts the expression of all sorts of genes involved in inflammatory response and cell proliferation/death. Boom, science.]</em></p><p>Zanos’s goal is to build implantable devices that can read out and decipher signals from the vagus nerve, then employ these devices as early diagnostic tools which can give doctors and algorithms access to high-quality health data.</p><p>Zanos’s group has made quite a bit of progress. They’ve run experiments in anesthetized rats or mice where they record directly from the rodent’s vagus nerve, rather than actually implanting a device. It’s worthwhile highlighting the anesthetization because the vagus nerve carries information about many things (I’ll talk more about the vagus nerve in <strong>The Literature</strong> section below). As I understand it, the more static a mammalian organism and its brain &amp; body function, the less noisy the vagus nerve activity, which is important for pioneering research. The vagus nerve recordings in anesthetized rodents followed ground-truth (i.e., traditional recording methods) very well for insulin and cytokines, and decently well for glucose.</p><p>The big challenge, it seems, is getting high-quality signals despite variation in vagus nerve anatomy. It was easier for Dr. Zanos and his team to record signals from mice than from rats, despite the fact that the mouse vagus nerve is 100µm, whereas the rat vagus nerve is 400µm. Likely, this is due to anatomical differences: mouse vagus nerves don’t have distinct fascicles/fiber bundles within the nerve, but rats do; additionally, rats have other connective tissue around, and inside of, the vagus nerve. This discrepancy suggests that high-quality recordings from humans will be particularly challenging, since our vagus nerve anatomy is even more complex.</p><p>Broadly, Zanos describes two next steps: improving the decoding algorithms used to interpret vagus nerve signals and developing the implant itself (as opposed to just anesthetizing rodents and temporarily inserting recording electrodes). This latter improvement will allow the team to record data from the vagus nerve over days, not just hours.</p><h3>The Literature</h3><p>I had fully intended to dive into Zanos’s work in detail, but upon scouring the interwebs, I realized that Zanos hasn’t yet published these results (you can check out more of his work on his <a href="https://sites.google.com/site/theozanos/home">website</a>, though!).</p><p>So, I’ll instead take this opportunity to talk about another use of stimulating/recording from the vagus nerve: fighting <strong>inflammatory disease</strong>.</p><p>Let’s first define some terms! (“Ew—,” you say. “Jargon,” you say)</p><ul><li><strong>Bioelectronic Medicine </strong>is the field, technologies, and medical techniques dedicated to treating disease and injury via electrical or electrochemical stimulation of neural or non-neural cells in the body, thereby impacting biochemical pathways and organ function. Alright, English: record from or stimulate cells in the body in order to support health. Easy. And really profound, because it’s much more targetable than drug treatment, and in many ways easier to develop. For a great overview, check out this <a href="http://neuralimplantpodcast.com/dr-manfred-franke-simply-explains-basics-about-neural-activation-therapy">really phenomenal interview</a> with Dr. Manfred Franke.</li><li><strong>Afferent/efferent </strong>are just terms to describe what type of information a nerve/axon carries (nerves are bundles of axons). Afferent means the nerve/axon is sending sensory information to the brain; efferent means the nerve/axon is sending motor information from the brain to the body. Here, “sensory” can mean anything ranging from temperature, to pressure, to the presence of chemicals in the blood stream, etc..</li><li>The <strong>vagus nerve </strong>is the 10th cranial nerve (the <a href="https://en.wikipedia.org/wiki/Cranial_nerves"><strong>cranial nerves</strong></a> are a set of important nerves, 10 of which originate in the brainstem). What makes the vagus nerve special amongst cranial nerves is that it sends nerve branches all throughout the body, and is involved in controlling and interpreting signals from organs like the spleen, liver, lungs, heart, etc. The vagus nerve sends <em>efferent</em> motor information from the brain/brainstem to the body and portions of the neck, and carries <em>afferent</em> sensory information back to the brain from the larynx/pharynx and other structures as well (and even from some organs in the body!).</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/750/1*g7RwgevcjYMzwU9fS3UuvQ.jpeg" /><figcaption>Image: <a href="https://www.sott.net/article/345640-The-vagus-nerve-and-how-it-impacts-health-mood-and-performance">https://www.sott.net/article/345640-The-vagus-nerve-and-how-it-impacts-health-mood-and-performance</a></figcaption></figure><ul><li><strong>Vagus Nerve Stimulation (VNS) </strong>is the application of electrical current to the vagus nerve in order to cause efferent (motor) signals to be sent to a particular organ. VNS has been used extensively to treat severe epilepsy, and is now being explored for other treatments as well.</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/344/1*dEWOTu1eejFRbY8Yv8DMFA.jpeg" /><figcaption>Image: <a href="https://emedicine.medscape.com/article/1875813-overview?pa=U7Veg2IsKmge8dDOhSfK%2BL4hwqQrNM1TU6POCCSkF8aOvMIh8Q4lUpaxMIhU6tDcb7X%2B2M1CV4Rslje1mvwZgiRhZLc6xjdjmi9FlNdSZuc%3D">emedicine.medscape.com</a>. (Note: that WHOLE yellow thing is the vagus nerve)</figcaption></figure><ul><li>The <strong>inflammatory response</strong> is the body’s response to foreign substances. Essentially, immune cells try to detect substances that aren’t supposed to be in the body, and if a foreign substance is identified the cells work to destroy it. This is a hugely complex topic, and there’s a ton of detail to it that I don’t nearly understand myself. Here’s an <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923430/pdf/nihms225107.pdf"><strong>overview paper</strong></a> that I haven’t read yet, but hopefully will one day soon when I have time (my backlog of papers literally scares me).</li><li><strong>Inflammatory diseases </strong>are a class of disease in which the body’s inflammatory response winds up damaging tissue within the body. Chronic examples of inflammatory disease are <a href="https://en.wikipedia.org/wiki/Crohn&#39;s_disease"><strong>Crohn’s disease</strong></a>, in which the immune system attacks tissue in the gastrointestinal tract, and <a href="https://en.wikipedia.org/wiki/Rheumatoid_arthritis"><strong>Rheumatoid Arthritis (RA)</strong></a>, where the immune system attacks joints. Dangerous acute inflammatory responses include <a href="https://en.wikipedia.org/wiki/Septic_shock"><strong>septic shock</strong></a>, in which bacterial infections causes a rapid and overcompensatory inflammatory response that drastically reduces blood pressure so much as to starve organs of blood.</li></ul><p>With this terminology in mind, let’s discuss an application of vagus nerve stimulation to treat inflammatory disease. This method has been pioneered by researchers at the Feinstein Institute (which is Zanos’s affiliated institution). With the help of his team, <a href="https://www.feinsteininstitute.org/our-researchers/kevin-j-tracey-md/">Dr. Kevin Tracey</a>—the President and CEO of the Feinstein Institute—has identified a particular pathway through which stimulating the vagus nerve can reduce inflammatory response in the body. He refers to it as the <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1783813/"><strong>cholinergic anti-inflammatory pathway</strong></a>. It’s named as such because: a) This pathway relies on the neurotransmitter <strong>acetylcholine (ACh) </strong>(hence, “cholinergic”), it works against inflammatory responses (hence, “anti-inflammatory”), and it entails a process involving multiple types of cells, proteins, and organs (hence, “pathway”). Take that, nomenclature!</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*t5LHFZ4Dd2eBUUy26601Yg.png" /><figcaption>Image: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1783813/">Tracey, 2007</a></figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*TZeoxKjPIDc65vwtquqUBA.png" /><figcaption>Image: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1783813/">Tracey, 2007</a></figcaption></figure><p>Here’s the idea (this is going to be a little messy, bear with me): Remember cytokines? We talked about those small proteins earlier in the post. Elevated levels of cytokines are associated with injury to tissue due to inflammatory response, as in the case of rheumatoid arthritis (the damage in rheumatoid arthritis comes from inflammation of the <a href="https://en.wikipedia.org/wiki/Synovial_membrane"><strong>synovial membrane</strong></a> in joints, resulting in the deterioration of cartilage and bone). If the vagus nerve is stimulated (*skipping over some unnecessary details*), ACh gets released onto the <strong>α7 subunit of the nicotinic ACh receptor (α7nAChR)</strong>. The Nomenclature Strikes Back.</p><p>This receptor then prevents the movement of NF-κB into the nuclei of <a href="https://en.wikipedia.org/wiki/Macrophage"><strong>macrophages</strong></a> (a type of immune cell)…which is important, because if NF-κB <em>were</em> to make it to the nucleus, it would produce more TNF and other cytokines that cause inflammatory responses in cells! Preventing NF-κB from entering the nucleus prevents the proliferation of inflammation, it would seem.</p><p>How does this fit in with Zanos’s work with cytokines? Well, Dr. Tracey has hypothesized that the vagus nerve also sends afferent (sensory) information about cytokine levels back to the brain—it’s keeping the brain up to date on the state of the body’s inflammatory response. Zanos’s work built on that hypothesis and sure enough, he was able to decode cytokine levels from the vagus nerve. (Here’s a <a href="http://molmed.org/video/206">video about some related work</a> from the Feinstein Institute.)</p><p>Anyways, back to stimulating the vagus nerve. Here’s the question: if we stimulate the vagus nerve of a patient with rheumatoid arthritis, will we see reduced symptoms and TNF levels, which are indicators of inflammatory response?</p><p><a href="http://www.pnas.org/content/113/29/8284">Koopman et al (2016)</a> set out to answer this. Spoiler alert, the study’s title gives away the results: <em>Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis</em>. Well, now that I’ve ruined the surprise, let’s learn a little more about what happened!</p><p>There were two groups: one group of patients had epilepsy, with no history of rheumatoid arthritis (RA) or inflammatory disease. The other group had RA.</p><h4>Non-RA patients</h4><p>First, the authors implanted a coiled cuff electrode from Cyberonics onto the left cervical vagus nerve of each control non-RA patient (cervical = near the cervical region of the spinal cord). The authors chose patients with epilepsy since VNS for epilepsy is a well-known and effective treatment. Seven patients (5M, 2F, mean age 35yrs (25yrs-43yrs range)) were anesthetized and administered endotoxin to stimulate monocyte production of TNF for four hours. Plain English: the researchers put some bad molecules into the patients that caused an inflammatory response. Measurements of TNF levels were taken at three points: before anesthesia, after anesthesia but before vagus nerve stimulation, and four hours after vagus nerve stimulation. As we can see in the graph below, VNS significantly reduced levels of cytokines TNF, IL-6, and IL-1ß as compared to pre-VNS. It’s also worth noting that the results couldn’t have been due to the placebo effect since the patients were under anesthesia.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ygpGOW3Y-HYPNstoy0DZyw.png" /><figcaption>Image: <a href="http://www.pnas.org/content/113/29/8284">Koopman et al, 2016</a>. (Note: “LPS” = <a href="https://en.wikipedia.org/wiki/Lipopolysaccharide">lipopolysaccharide</a>, aka endotoxin)</figcaption></figure><p>The goal of this part of the study was to determine whether, in patients without inflammatory disease, VNS could reduce cytokine levels. The results were clearly positive.</p><h4>Rheumatoid Arthritis patients</h4><p>Two cohorts were created of n = 17 patients (originally 18, but one was later excluded). Cohort I (n = 7) were patients with early-middle stage RA who had failed typical <a href="https://en.wikipedia.org/wiki/Methotrexate"><strong>methotrexate</strong></a> therapy (a drug for treating RA); these patients had never been treated with TNF antagonists (substances that inhibit, or antagonize, TNF) or had previously stopped TNF treatment due to toxic reactions to the drug. Cohort II (n = 10) were patients who failed <em>both</em> conventional methotrexate therapy <em>and</em> at least two different types of drug-based TNF antagonization treatments.</p><h4>Method</h4><p>The protocol was as follows:</p><ul><li>Surgery was performed on Day -14 (you read that correctly: “negative fourteen”).</li><li>On Day 0, one round of 60 seconds of stimulation was administered with 250µs pulses at 10Hz, using output current from 0.25–2.0mA, depending on the patient’s tolerance (for those of us who, like me, are lacking in the physics department: 1µs =1 microsecond = one one-millionth of a second; 1Hz = once per second; 1 mA = one one-thousandth of an Ampere, which is a measure of the amount of charge flowing through a substance per unit time).</li><li>On Day 7, the output current was increased up to 2.0mA, and subsequently delivered daily for 60s with the same stimulus profile as before.</li><li>Every week, up until Day 28, the current was escalated until it hit a maximum of 2.0mA.</li><li>At Day 28, for patients who had failed to respond thus far transitioned to a 4x daily vagus nerve stimulation. In Cohort II, 6/10 patients were increased to 4 daily pulses.</li><li>At Day 28, the output current was 1.29 +/- 0.37mA for Cohort I and 1.60 +/- 0.36mA for Cohort II.</li><li>After Day 42, the stimulator was turned off for 14 days.</li><li>At Day 56, the stimulator was turned back on and the previous stimulation protocol was completed until Day 84.</li></ul><h4>Results</h4><p>On Day 42, across the combined Cohort I &amp; II groups, TNF levels were significantly reduced from the baseline at Day -21 (p &lt; 0.05).</p><ul><li>Day -21 ==&gt; TNF = 2900 +/- 566 pg/mL (picograms / milliliter)</li><li>Day 42 ==&gt; TNF = 1776 +/- 342 pg/mL</li></ul><p>By Day 56, after the stimulator was turned off on Day 42, TNF levels had risen again. Then, upon turning the stimulator back on, the TNF levels fell once more. This observation evidences the causal effect of VNS on TNF production, and therefore inflammatory response.</p><p>In addition to measuring TNF levels, researchers looked at the rheumatoid arthritis signs &amp; symptoms. They used the standard <a href="https://www.rheumakit.com/en/calculators/das28_crp">28-joint C-reactive protein-based disease activity score (DAS28-CRP)</a>. This score counts swollen and tender joints, asks the patient to define a visual analog to the disease’s activity, and measures serum C-reactive protein levels. As one would hope, the DAS28-CRP scores also rose and fell in the same pattern as TNF production, further evidencing the value of VNS for rheumatoid arthritis treatment!</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*aLcwOUYNWambFpEwDK9IBQ.png" /><figcaption>Image: <a href="http://www.pnas.org/content/113/29/8284">Koopman et al, 2016</a>. (Note: “LPS” = <a href="https://en.wikipedia.org/wiki/Lipopolysaccharide">lipopolysaccharide</a>, aka endotoxin)</figcaption></figure><p>I’d encourage you to take a moment and check out the graphs (reading the description below each graph really helps!). In particular, I find it compelling how the treatment hiatus beginning on Day 42 saw an increase in symptoms/TNF until the VNS was turned back on — this is strongly indicative of causality.</p><p>Finally, it’s worth noting the unfortunate fact that Cohort I saw larger impacts from the VNS than did Cohort II. This makes sense given Cohort I was in an earlier stage in the disease. On the one hand, it would be even more exciting if VNS could treat late-stage RA just as well as early-stage RA. On the other, though, I’d be curious to know whether or not long-term intervention in Cohort I slows progression of the disease.</p><h3>Rumination…</h3><h4>well, not this time, actually!</h4><p>When I set out to write this post, my full intention was to include a robust Rumination section. But then, as part of my research before writing, I took a deep dive into bioelectronic medicine and haven’t yet climbed back out of the pool. BEM is a complex and exciting topic.</p><p>Once I feel I have a handle on the relevant technologies, opportunities, and implications, I’ll write something extensive about it. I wouldn’t be doing these topics justice right now given my current ignoramus-ness.</p><p>In the meantime, I’ll leave you with some motivation for why bioelectronic medicine is worth paying attention to. In 2015, $328.4bn was spent on prescriptions in the US. Bioelectronic medicine treatments, which leverage electrical stimulation of the nervous system to create desired effects in the body, can take 1/3 the time of drug-based treatments to develop and get FDA approval for. Furthermore, unlike pharmaceuticals, precise nervous system stimulation doesn’t directly release molecules into the bloodstream, so the potential for severe side-effects is diminished.</p><p>I think there’s a revolution coming in healthcare treatments, and that revolution is bioelectronic medicine. Stay tuned for more…</p><h3>In Conclusion</h3><p>In this post, I discussed Dr. Theos Zanos’s research into decoding glucose, insulin, and cytokine levels by recording from rodent vagus nerves. We explored a research paper from another domain of vagus-nerve-based bioelectronic medicine, in which the vagus nerve is stimulated to treat inflammatory disease. Finally, I offered up a little motivation for why bioelectronic medicine is a field to pay attention to, but held off from saying much more pending further research on my end.</p><p>One of my primary goals with The Substrate is to encourage an ethics-first conversation about brain computer interfaces. To that end: comment, write me at <a href="/service/mailto:hello@thesubstrate.com">hello@thesubstrate.com</a>, or find me on twitter (@averybedows). I will respond! (seriously, I will).</p><p>Until next time,</p><p>Avery</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3a198e4da4f3" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-substrate/when-a-nerve-can-be-your-glucometer-3a198e4da4f3">When a nerve can be your glucometer</a> was originally published in <a href="https://medium.com/the-substrate">The Substrate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Paralysis is no match for Guitar Hero]]></title>
            <link>https://medium.com/the-substrate/paralysis-is-no-match-for-guitar-hero-e03d5efcac82?source=rss-c7506c12d100------2</link>
            <guid isPermaLink="false">https://medium.com/p/e03d5efcac82</guid>
            <category><![CDATA[cognitive-science]]></category>
            <category><![CDATA[neurotechnology]]></category>
            <category><![CDATA[neuroscience]]></category>
            <category><![CDATA[bioengineering]]></category>
            <category><![CDATA[brain]]></category>
            <dc:creator><![CDATA[Avery Bedows]]></dc:creator>
            <pubDate>Tue, 06 Mar 2018 01:54:26 GMT</pubDate>
            <atom:updated>2018-05-14T22:56:05.224Z</atom:updated>
            <content:encoded><![CDATA[<p>In 2010, Ian Burkhart suffered a broken neck from a diving accident, and was left with a C5 spinal cord injury that resulted in paralysis from the elbow, down.</p><p>Four years later, his skull was opened and a neural implant was inserted. Now, Ian can play Guitar Hero.</p><p>Ladan Jiracek, host of the <a href="http://neuralimplantpodcast.com/">Neural Implant Podcast</a>, talked with Ian at the 2017 Society for Neuroscience conference. Together, they explored the Ian’s, and the psychology around having a neural implant.</p><p><strong>Tl;dr: in this post, I’ll discuss how a neural implant has helped a quadriplegia patient play Guitar Hero, then discuss my thoughts on this incredible feat!</strong></p><h3>The Episode</h3><p>In <a href="http://neuralimplantpodcast.com/ian-burkhart-on-what-its-like-to-be-implanted-and-to-move-your-hands-with-an-implant">this episode</a> of the Neural Implant Podcast, Ladan and Ian begin by discussing Ian’s incredible claim-to-fame: a brain computer interface has enabled him to <a href="http://www.sciencemag.org/news/2016/04/brain-implant-helps-quadriplegic-play-guitar-hero">play guitar hero</a>, despite his quadriplegia. This process has taken years of training, and requires both a cortical implant (i.e., a Utah array implanted in Ian’s left motor cortex) and a custom-built array of 130 electrodes wrapped around his right forearm.</p><p>The ground-breaking work was part of a study led by <a href="http://neuralimplantpodcast.com/dr-chad-bouton-on-teaching-paralysed-people-to-play-guitar-hero">Dr. Chad Bouton</a> of the <a href="http://feinsteininstitute.org/">Feinstein Institute</a>, and its success was the result of a large collaborative effort between a multidisciplinary set of engineers, researchers, and surgeons.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/210/1*X3JWA5OiXXfGXe336u4UVA.jpeg" /><figcaption>Image: <a href="https://www.feinsteininstitute.org/our-researchers/chad-bouton/">The Feinstein Institute</a>—Dr. Chad Bouton!</figcaption></figure><p>When Ian was first approached about participating in the study, despite the world-class researchers, he faced a difficult decision: surgeries — especially brain surgeries — are risky. There was no guarantee that the implant-enabled system would work, and it would take many months of training before Ian <em>might</em> see therapeutic improvements. Ian could have continued living his life, and making the most of it, without the risk.</p><p>Ian chose to go under the knife; his nerves were calmed, in part, by meeting with the neurosurgeon who would be performing the operation. This surgeon routinely inserts electrodes for <a href="https://en.wikipedia.org/wiki/Deep_brain_stimulation">deep-brain stimulation</a> (a method of alleviating symptoms of Parkinson’s Disease involving an invasive neural implant), and these electrodes travel far into the brain; a surgery that “only” involves inserting an electrode array into the surface of the cortex would be proverbial cake!</p><p>So, Ian gave it the good ol’ thumbs-up. Since receiving the surgery, he has spent 3.5 years working with the research team to improve the neural implant system. Although his training regiment of three days per week, for 3–4 hours a day, has been exhausting, Ian has made tremendous progress. He can perform everyday tasks (e.g. picking up a toothbrush), he can play Guitar Hero (!), and it’s now second nature for him to perform simple actions like opening/closing his hand just by imagining it.</p><p>Right now, Ian can’t take this setup out of the lab because there are still miniaturization and regulatory hurdles. But he feels strongly that the additional mobility given to him by the neural implant could significantly improve his daily life, and in the lives of many other patients in similar positions.</p><h3>The Literature</h3><p>Here, we’ll get a little bit technical and talk about a 2016 paper that reported on Ian’s progress and the amazing work of the team behind the implant. Lead-authored by Dr. Bouton, <a href="https://www.researchgate.net/profile/Marcie_Bockbrader/publication/301247939_Restoring_cortical_control_of_functional_movement_in_a_human_with_quadriplegia/links/59d70c77a6fdcc52acaa0075/Restoring-cortical-control-of-functional-movement-in-a-human-with-quadriplegia.pdf">the paper</a> titled <em>Restoring cortical control of functional movement in a human with quadriplegia </em>dives into the details about this system for returning motor control to paralysis patients.</p><h4>Implantation</h4><p>Before the scientists could implant the electrode array, they had to determine precisely where to insert it. It’s known that signals to control motor output (i.e., moving some part of your body) generally occur in the <strong>primary motor cortex</strong> (intentions to move, more or less, show up in the <strong>premotor cortex</strong>). Sure enough, when the researchers placed Ian in an <a href="https://en.wikipedia.org/wiki/Magnetic_resonance_imaging">MRI scanner</a> and asked him to repeatedly imagine performing certain hand motions with his right hand (remember: he’s paralyzed, so he wasn’t actually performing these motions), they saw activation in a particular region of the left primary motor cortex, which is often abbreviated “left M1”. (One additional note: the mammalian brain uses contralateral representations…in other words, if I’m moving my right arm, the left hemisphere of my brain is mainly responsible for controlling it.)</p><p>With this assurance, Ian went under the knife. During surgery, the surgeon decided the precise placement of the electrode array, determined in part by the knowledge gained from the MRI scanner, and in part based on the surgeon’s visual identification of a location that wouldn’t damage major cerebral arteries. In the image below, the red regions indicate those which were activated while Ian imagined movement; the small green region is the footprint of the electrode array; the yellow region represents the overlap between the red and green regions.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/716/1*jdHAWmUSzDUg0mLU87JyNg.png" /><figcaption>Image: Bouton et al., 2016</figcaption></figure><p>As mentioned above, the implanted device was a Utah Array, manufactured by <a href="http://blackrockmicro.com/">Blackrock Microsystems</a> (this device is the current standard for clinical implantation in humans). (A jargon explanation: “clinical” means “used to treat people.”)</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*69b6KNedo4QwYGrPPu6X0g.jpeg" /><figcaption>Image: <a href="https://continuum.utah.edu/web-exclusives/the-bionics-man/">https://continuum.utah.edu/web-exclusives/the-bionics-man/</a></figcaption></figure><h4>The set-up</h4><p>Ian’s neural interface has two major components: the electrode array in his left M1, and an array of 130 electrodes wrapped around his right forearm.</p><p>When Bouton and his colleagues are recording from Ian’s brain, they connect a wire to a piece of hardware protruding from his skull. This wire, in turn, connects to a piece of hardware referred to as the <strong>headstage</strong>, which does initial amplification of the analog signal; the headstage then connects to another amplifier and signal processor called a NeuroPort, which in turn plugs into a computer. See the Blackrock <a href="http://blackrockmicro.com/neuroscience-research-projects/human-research-systems/%23bmi">website</a> for details on a generic Utah Array + NeuroPort setup.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/604/1*0A01VbBfMNiP2eki17YY5A.png" /><figcaption>Image: Blackrock Microsystems (<a href="http://blackrockmicro.com/neuroscience-research-projects/human-research-systems/#bmi">http://blackrockmicro.com/neuroscience-research-projects/human-research-systems/#bmi</a>)</figcaption></figure><p>The second major component of Ian’s system is an array of 130 surface (non-implanted) electrodes wrapped around his right forearm. These electrodes can run different electrical stimulation patterns through his forearm muscles, therefore causing them to contract in a variety of ways. In total, different stimulation patterns can produce different hand movements.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/482/1*BYyMCjLdkOmz_OD_1Bl9SQ.png" /><figcaption>Image: Bouton et al., 2016</figcaption></figure><h4>Training</h4><p>For the last 3.5 years, Ian has trained to perform six separate movements with this neural implant. The training paradigms weren’t fully specified in this paper; in general, however, the setup entails Ian sitting in front of a monitor that displays virtual hand movements. His goal, therefore, is to mimic the hand movements on the monitor.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/474/1*gaxXbP7bzmef5iUPCa5g1w.png" /><figcaption>Image: Bouton et al., 2016</figcaption></figure><p>In the podcast, Ian mentions that the research team leverages mirror neurons by having a researcher sit next to Ian and make the movements he’s supposed to make. For the uninitiated (i.e., me until very recently), mirror neurons are neurons in the premotor cortex that respond when someone <em>else </em>makes a movement, in addition to when <em>you</em> make that movement. See <a href="https://www.ncbi.nlm.nih.gov/pubmed/24778385">this review</a> for more detail. The Bouton et al. paper does note, however, that mirror neurons are not required for Ian to actually execute the movements, since he can be given textual or auditory cues and still perform the tasks.</p><h4>Measurements</h4><p>The team set up a camera overhead to record Ian’s hand movements. To track his progress over time, they devised a benchmark task in which Ian has to perform 5 blocks of the 6 hand movements, with each movement being presented in random order. Three measures of effectiveness are employed.</p><ol><li>Based on video recordings, the researchers look at the percentage of video frames during which Ian’s hand movements match the cued hand movements — this is referred to as <strong>Accuracy</strong>. Accuracy can be decomposed into <strong>Sensitivity</strong> and <strong>Specificity</strong>; the former refers to the chunk of Accuracy that falls <em>during</em> the visual cues themselves, and the latter refers to the chunk of Accuracy that falls <em>outside</em> of the period during which the visual cues were displayed.</li><li>The researchers utilized a “<strong>functional movement task</strong>” to determine how well Ian would be able to perform a real-world movement. The task they chose was for Ian to pick up a bottle, pour dice from that bottle into a jar, then pick up a stick to stir the contents of the jar, then set the stick back down. Equivalent, it seems, to pouring cream into coffee.</li><li>A psychiatrist performed a standardized <strong>Manual Muscle Test (MTT)</strong>, known as the <a href="http://www.grassptest.com/">Graded and Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP)</a>. In general, this test measures upper limb sensorimotor function. Five domains of movement are examined:</li></ol><ul><li>Strength</li><li>Dorsal (back) sensation</li><li>Ventral (front) sensation</li><li>Gross grasping ability, aka “qualitative prehension” (something like, “qualitatively, how good are you at picking things up?”),</li><li>Prehensile skills (something like, “quantitatively, how good are you at picking things up?”).</li></ul><h4>Results</h4><p>Ian and the research team achieved the following results:</p><p><strong>Overall accuracy: </strong>The range was 93.1 +/- 0.5% (p &lt; 0.01) for wrist flexion…to 97.3% +/- 0.3% (p &lt; 0.01) for thumb flexion (wrist flexion and thumb flexion are two of the six movements Ian has learned to perform for this assessment)</p><p><strong>Sensitivity</strong> (accuracy during the presentation of the cue): The range was 32.9 +/- 3.8% for thumb extension…to 81.9 +/- 2.6% for wrist extension (note the big difference in success between thumb extension and wrist extension — this is <em>total</em> speculation, but maybe this is because thumb extension requires finer-scale muscle movements than wrist extension. This hypothesis was inspired by my very scientific methodology of moving my thumb, and then my wrist, and then my thumb again. Did I mention this is speculative?)</p><p><strong>Specificity</strong> (accuracy when the cue wasn’t presented): The range was 94.8% +/- 0.5% for wrist flexion….to 99.8 +/- 1.0% for thumb flexion</p><p><strong>GRASSP:</strong></p><ul><li>Ian’s apparent <strong>strength</strong> improved from that associated with a C6 spinal cord injury to that associated with a C7-C8 spinal cord injury</li><li>Ian’s <strong>gross grasping ability</strong> improved from that associated with a C7-C8 spinal cord injury to that associated with a C8-T1 level spinal cord injury</li><li>Ian’s <strong>prehensile skills</strong> improved from those associated with a C5 spinal cord injury to those associated with a C6 level spinal cord injury</li><li>A quick note on interpretation: C6, C7, C8, T1, etc. are all levels of the spinal cord, and each level of the spinal cord sends out different <strong>efferent/motor nerves</strong> to the body via its <strong>ventral roots</strong>, and receives different <strong>afferent/sensory nerves</strong> via its <strong>dorsal roots</strong>. If the spinal cord is injured at a specific location, it means that sensory information from below the injury <em>can’t travel up to the brain</em>, and motor information coming down from the brain <em>can’t travel past the spinal cord lesion</em> (lesion is just a fancy term for “injury” or “tumor” or “something that’s causing a disruption in the normal functioning of the nearby cells”). That’s why it’s such a meaningful improvement that, for example, Ian’s strength improved from a C6 injury to a C7-C8 injury — it’s as if the injury is lower on his back, and there are fewer spinal cord segments that can’t communicate with his brain!</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/496/1*Ofwj_Fb2n8kRlqLfuulyEQ.jpeg" /><figcaption>Image: <a href="https://anatomybodysystem.com/brain-and-spinal-cord-diagram/brain-and-spinal-cord-diagram-anatomy-chart-of-spinal-cord-labeled-anatomy-diagram-pics/">https://anatomybodysystem.com/brain-and-spinal-cord-diagram/brain-and-spinal-cord-diagram-anatomy-chart-of-spinal-cord-labeled-anatomy-diagram-pics/</a></figcaption></figure><p><strong>Functional movement task</strong> (similar to pouring cream into a cup of coffee and stirring): Ian was able to compete this task 3/5 times, in 42 +/- 10s each time.</p><p>As we see from the quantitative results, this study describes a neural interfacing system that offers tremendous opportunity to improve the quality of life for a patient with quadriplegia. If you have an opportunity to listen to <a href="http://neuralimplantpodcast.com/ian-burkhart-on-what-its-like-to-be-implanted-and-to-move-your-hands-with-an-implant">this episode of the podcast</a>, you’ll hear Ian testify as much!</p><h3>Ruminations</h3><h4><em>What’s it like to have a neural implant?</em></h4><p>Obviously, there aren’t many people who can answer this question in the way that Ian can.</p><p>Brief pause for a runaway tangent: here, I’m considering cortical implants, as opposed to non-cortical implants. Many people have non-cortical neural implants—the most prolific are <a href="https://en.wikipedia.org/wiki/Cochlear_implant">cochlear implants</a>, which have helped ~400,000 patients so far with no, or diminished, hearing. By way of brief overview, the <strong>cochlea</strong> is a small spiraled structure deep within the ear that turns sound into neural signals. Cochlear implants contain electrodes that get <a href="https://blog.medel.com/photographic-tour-of-the-cochlea/">embedded</a> into the cochlea, then stimulate the auditory nerve based on sound picked up by a microphone (instead of the damaged organic human ear). The auditory nerve carries neural signals about sound from the inner ear to the <strong>cochlear nucleus</strong> in the <strong>brainstem</strong>, then eventually to the <strong>thalamus</strong>, then to the <strong>auditory cortex</strong>. Sorry, that was a lot, I just find sensory pathways particularly <em>awesome</em>.</p><p>Returning from our runaway tangent…Ladan, the host of the Neural Implant Podcast, has interviewed one of the other rare humans who’s had the opportunity to use an experimental nervous system implant, Dr. Kevin Warwick. Dr. Warwick was <a href="http://neuralimplantpodcast.com/dr-kevin-warwick-on-how-he-became-the-worlds-first-cyborg">the first human cyborg</a>, and although his implant was in his arm and rather than his cortex, he used the implant for something the cortex usually does: communicating with another person! Dr. Warwick and his wife both implanted electrodes into their arms, and when one squeezed their forearm muscle, the other’s arm would feel it. This is simple, but it’s profound (profound because any kind of nervous-system-to-nervous-system communication seems pretty profound to me).</p><p>In my view, the fact that so few people have experience with advanced neural implants is a significant issue. I think that the path to ethical BMI involves a very gradual rollout that includes extensive interviews with patients about their experiences using neural interfaces. This is similar in sentiment to how user experience design is undertaken in software development: build a prototype, give it to some users, get buckets of feedback from them, and make modifications to the product accordingly — all before opening up the product to the public. It’s relevant to note that Ian feels as though he’s become a part of the research team, as opposed to just a patient; this is an embodiment of the UX design approach, where the user plays an integral role in product development (although it admittedly feels painfully trivializing to use e.g. iOS app development terminology to describe a subject as weighty as putting technology into someone’s brain for therapeutic purposes).</p><p>Perhaps one step forward in our society’s journey towards ethical BMI introduction is to create a regulatory/government-facilitated roadmap for rolling out new interfaces. This roadmap could, in part, specify protocols for interviewing users at each stage, with the protocols based on existing user research methodologies in the technology field. <strong>If we’re going to be changing the experience of being a person, we damned well better ask people what that new experience is like</strong>, and perhaps even build regulation around that inquiry process.</p><h4><em>The earliest and most vocal proponents of neural interfaces will be…patients using neural interfaces.</em></h4><p>Maybe this feels obvious, but I think it’s important nonetheless. In his interview with Ladan, <a href="http://neuralimplantpodcast.com/matt-angle-ceo-of-paradromics-on-their-18-million-darpa-grant-for-broadband-for-the-brain">Matt Angle from Paradromics</a> hypothesizes that once millions of people are using BMIs for therapeutic purposes, the public will start really paying attention, and start to ask questions about enhancement/augmentation. I think the mechanism by which this hypothesis will turn into a verified thesis is that of enthusiastic testimonials, akin to “oh my gosh, this cataract surgery was <em>amazing</em>!”.</p><p>Unlike the development of other massively-influential technologies like the smartphone, BMI development will be driven by truly dire need. The improvement to a human life a BMI could bring is, to use a linguistically demonstrative but non-mathematical back-of-the-napkin calculation, at least an order of magnitude greater than the improvement a smartphone brings. Therefore, there will be significant market demand — and <strong>my best guess is that advocacy for neural implants within the public domain won’t come from organizations or politicians as much as it will come from the benefactors of neural implants: patients</strong>. I’m not sure if there’s precedent for a technology that has the data/security/post-humanity implications of e.g. the internet or Facebook, and the human life implications of medical technology.</p><p>That’s why I find this notion of patient-as-proponent to be significant: I don’t think it’s ever happened before. If you have thoughts on how this might play out (or if you think I’m entirely wrong, and clearly something else is going to happen instead), <em>please write me</em>!</p><h4><em>Learning to use a BMI is exhausting.</em></h4><p>In the interview, Ian comments that his training can be both boring and exhausting, a 10/10 combination if there ever were one. Broadly, this is due to the fact that in order to control a closed-loop neural implant system (closed loop = motor control + some kind of visual, somatosensory, or neural feedback), your brain has to undergo plasticity. That takes time, and energy.</p><p>Ian remarks that playing Guitar Hero was a far more enjoyable training task than, e.g., the GRASSP assessment. This makes me think that, for widely usable BMIs (therapeutic or otherwise), there will need to be a <em>fun</em> on-boarding process. Otherwise, patients won’t want to use the technology and therefore outcomes won’t be maximized. I see this as another scenario where commercialized/large-scale BMIs could take cues from technological product development.</p><h4><em>In order for BMIs to advance, people need to make personal decisions to take a risk.</em></h4><p>To directly quote Ian: “Research isn’t going anywhere unless you have individuals that are willing to do something that might be seen as risky.” This starkly contrasts other domains of research, such as computer science. For example, there’s currently a raging debate about the ethics and safety of artificial intelligence; but, regardless of public discourse, large companies like Google and Facebook are eagerly composing world-class teams of AI researchers whose progress is limited mostly by the rapidity with which their fingers klick-clack on a keyboard, and by how many processors they can use to train their algorithms. BMI development, on the other hand, can’t go anywhere unless people <em>want it — </em>it requires consent. The basic research here requires consent, and this might be an automatically-enforced method of democratic conversation…<strong>the amount of progress made in human BMI research will be proportional to the human demand for it. </strong>(An immediate objection to this point: “Oh, but there will be demand amongst the socioeconomically advantaged…and that will just create a bigger socioeconomic rift when the already-rich-and-powerful get augmented with neurotechnology, but everyone else doesn’t.” Really valid objection, and my tentative response to myself here is that: 1) for the foreseeable future, most BMI research will be therapeutic and not augmentative; 2) therapeutic BMI applications can be covered by insurance, which drastically reduces the financial burden of BMIs and therefore reduces the potential for socioeconomically-stratefied integration of BMIs into our society, as well).</p><h3>In Conclusion</h3><p>Yikes, that was a long one. In this post, I discussed Ladan’s <em>super</em> interesting interview with Ian Burkhart, an inspiring individual who’s made enormous progress in overcoming his quadriplegia with the assistance of a neural implant and the incredible team behind it. We dived in-depth into a paper describing Ian and his implant system, and I then offered up some thoughts seeded by the interview.</p><p>One of my primary goals with The Substrate is to encourage an ethics-first conversation about brain computer interfaces. To that end: comment, write me at <a href="/service/mailto:hello@thesubstrate.com">hello@thesubstrate.com</a>, or find me on twitter (@averybedows). I will respond! (seriously, I will).</p><p>Until next time,</p><p>Avery</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e03d5efcac82" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-substrate/paralysis-is-no-match-for-guitar-hero-e03d5efcac82">Paralysis is no match for Guitar Hero</a> was originally published in <a href="https://medium.com/the-substrate">The Substrate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[CorTec and the human/AI fusion]]></title>
            <link>https://medium.com/the-substrate/cortec-and-the-human-ai-fusion-fd38d9320e43?source=rss-c7506c12d100------2</link>
            <guid isPermaLink="false">https://medium.com/p/fd38d9320e43</guid>
            <category><![CDATA[neuroscience]]></category>
            <category><![CDATA[brain]]></category>
            <category><![CDATA[artificial-intelligence]]></category>
            <category><![CDATA[neurotechnology]]></category>
            <category><![CDATA[cognitive-science]]></category>
            <dc:creator><![CDATA[Avery Bedows]]></dc:creator>
            <pubDate>Thu, 01 Mar 2018 21:49:56 GMT</pubDate>
            <atom:updated>2018-03-01T22:47:18.277Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*9Ku_1VyUfUHu7GU_LDEGoA.jpeg" /><figcaption>Image: <a href="http://www.businessinsider.com/biggest-challenges-human-artificial-intelligence-2016-2">http://www.businessinsider.com/biggest-challenges-human-artificial-intelligence-2016-2</a></figcaption></figure><p>A human and a computer walk into a chat room…</p><p>Tl;dr: in this post, I’ll discuss a neurotechnology company called CorTec and their quest for human/AI fusion, then offer some thoughts on the latter.</p><p>At Society for Neuroscience 2017, Ladan Jiracek of the <a href="http://neuralimplantpodcast.com/">Neural Implant Podcast</a> <a href="http://neuralimplantpodcast.com/dr-joern-rickert-talks-about-cortec-and-their-implantable-soft-arrays">interviewed Dr. Jörn Rickert</a>, the CEO of <a href="http://cortec-neuro.com/">CorTec</a>. CorTec is a six-year-old company that designs and produces neural implants; they’re based in Germany, and their technology builds upon a decade of foundational university research and development — i.e., they’re academics who’ve taken their expertise and brought it to industry.</p><p>CorTec has spent years working on the <strong>CorTec Brain Interchange</strong>, a closed-loop, all-in-one neural interface whose creation pursues the lofty and intriguing goal of fusing humans with artificial intelligence.</p><h3>The Episode</h3><p>First up: let’s dive into the technology that CorTec has been developing! Currently, the company specializes in and sells soft, configurable <a href="https://en.wikipedia.org/wiki/Electrocorticography">electrocortigraphic (ECoG)</a> electrode arrays. ECoG is a specific type of intracranial (within the skull) neural recording device that sits on top of the brain’s cortex (which is the outer-most layer). The notion that it sits <em>atop</em> the cortex instead of <em>within</em> the cortex or deeper brain structures is important! Why? Because it comes with tradeoffs. ECoG is less invasive than other implants because it doesn’t penetrate brain tissue; however, it can only record from larger populations of neurons at the surface of the cortex.</p><p>For their upcoming innovative product, the CorTec Brain Interchange, CorTec has chosen a specific ECoG configuration. Below is an image of the entire flattened implant, and an image of it disassembled into parts.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*fptZudk9cHeJ0iisUKkn7Q.png" /><figcaption>Image: cortec-neuro.com/en/solutions/solutions-industry/electrodes</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*teqwEuprmaJE3ild68IGRg.png" /><figcaption>Image: cortec-neuro.com/en/solutions/solutions-industry/electrodes</figcaption></figure><p>With the CorTec Brain Interchange, the company is moving into a more advanced, and exciting, product area: they’re incorporating this electrode array into a system capable of recording from the brain intracranially, outputting that signal to a wearable computer which can decode neural information, and stimulating the brain based on the recorded information — all in realtime. Let’s abbreviate “CorTec Brain Interchange” with “CBI,” to preserve sanity.</p><p>The CBI has three components: a soft ECoG array with 32 channels (each channel can record or stimulate neural activity), an “internal control unit” that receives signals from the ECoG array (“internal” because it sits within the patient’s skull), and a small externally visible unit attached to the head that a) <a href="https://en.wikipedia.org/wiki/Wireless_power_transfer">inductively powers</a> the internal control unit, and b) communicates with a computer pack that performs computations based on the ECoG recordings.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*EORvbdopiqppEam1OMwzGw.png" /><figcaption>Image: <a href="http://cortec-neuro.com/en/public/cortec-bic">http://cortec-neuro.com/en/public/cortec-bic</a> — we see the ECoG array (top component), the internal control unit and its outside covering (bottom, with the halo), and an additional electrode presumably used for stimulating different deep brain structures (up/left).</figcaption></figure><p>As part of their research/development and for regulatory reasons, CorTec first has to test these implantable devices in animals before they can be used in humans. Jörn commented that CorTec has been able to leave the ECoG array in a sheep for ~1.5 years to date, and <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868924/">impressively</a>, when the ECoG array was removed, the device came out looking like new. CorTec will be pursuing human trials of their product in 2018, pending European regulatory approval.</p><p>As a quick aside: sheep are <a href="http://www.cam.ac.uk/research/features/counting-on-sheep">frequently used to test neural implants</a>. They’re intelligent animals with large brains, and have primate-like cortical folds, in addition to primate-like deep brain structures (i.e., the basal ganglia). Therefore, they provide a way to understand the safety and effectiveness of a neural implant before implanting into a human and risking a human life. Here’s a visual comparison of brains from different species — note the similarities! If you want to read more about the relationships between different species’ brains, check out <a href="https://www.frontiersin.org/articles/10.3389/neuro.09.031.2009/full">this paper</a>.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ctXPHmrnYI6bEnwzQf3lHQ.jpeg" /><figcaption>Image: Herculano-Houzel, 2009 (<a href="https://doi.org/10.3389/neuro.09.031.2009">https://doi.org/10.3389/neuro.09.031.2009</a>)</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*f54NbQsQqqX9JlemjCUMNg.jpeg" /><figcaption>Image: <a href="http://anatomycorner.com/main/image-gallery/sheep-brain/">http://anatomycorner.com/main/image-gallery/sheep-brain/</a>—this is a sheep brain, which I included for good measure, since there were no sheep brains in that other image (above this one) with oodles of brains.</figcaption></figure><p>So, returning from our sheep brain detour…what’s special about the Brain Interchange? As I understand it, it’s a combination of two things: ergonomics and algorithms. In terms of ergonomics: the CBI brings together a number of important technological components into one simple package. They have a biocompatible electrode array (i.e., the brain doesn’t try too hard to reject the array, the process of which damages electrodes and reduces their ability to record/stimulate), an inductively powered controller (this is important because patients with this implant won’t have to have a battery pack implanted), the ability to stimulate <em>and</em> record from the same electrodes (this is important for applications like controlling a prosthetic limb, where a patient needs to be able to <em>control</em> the limb and also <em>feel</em> what the limb is touching), and a conveniently attached computer pack. To put this intuitively, if CorTec ever decides to advertise via infomercials, they’ll probably use the phrase “All in one!” (for only three payments of $19.99, etc.).</p><p>The computer pack, in my view, is the most compelling part — and also goes the longest way towards achieving CorTec’s mission of AI/human fusion (which, as I’ll reflect on below, bears tremendous ethical and political implications). Traditionally, in order to interpret neural signals and decide how to stimulate the brain in response, researchers need a large equipment array in a laboratory setting. Currently, this makes it implausible for patients with neural implants to leave the laboratory and access the implants’ therapeutic value in their daily lives. CorTec’s wearable control system (similar in aesthetic to the wearable computer being developed by mixed reality company <a href="https://techcrunch.com/2017/12/20/magic-leap-shows-off-its-magic-leap-one-creators-edition-ar-headset-shipping-in-2018/">Magic Leap</a>) opens up the opportunities for a patient to take their therapeutic benefits out of the laboratory.</p><p>And then there’s the artificial intelligence component: sitting in this wearable computer are a series of algorithms that help interpret complex neural signals recorded by the ECoG array, and thereby decide the best way to stimulate the brain. As articulated on their website, these algorithms make the CorTec Brain Interchange a “responsive system,” so that the “therapy [can be] adjusted to [the] current need” of the patient. In other words: instead of indiscriminately stimulating the brain based on a best-guess of a patient’s symptoms, these algorithms intelligently decide when to intervene and when to leave the brain to its own devices (get it? devices? medical devices?).</p><p>This application of artificial intelligence (/machine learning) algorithms is far from dystopic science fiction in that it has limited functionality and real therapeutic value. It’s clear, however, that Jörn and his team at CorTec are thinking about future-facing implications of their work. Jörn reflects:</p><blockquote>“As Elon Musk said, we need to probably enhance ourselves to be able to compete with AI, and not become outmatched by them…and that’s essentially a political debate…Personally, I would say that — at least what we had in mind when we started CorTec — it’s about helping patients.”</blockquote><p>So, let’s take this cue to dive into the topic of human enhancement.</p><h3>Ruminations</h3><p>The idea of enhancing the human brain, especially by fusing it with artificial intelligence, has existed in the annals of science fiction and science reality for a long time. We see it in non-implantable forms, such as with Iron-Man-suit-wearing Tony Stark and his AI, Jarvis. Tony’s physical abilities are of course augmented by his suit, but he frequently tells Jarvis to handle complex tasks he can’t focus on in the moment, thereby “enhancing” his intellect (which, frankly, is already pretty extraordinary).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/672/1*iekvB8CdkpegHp7eNmm1RA.jpeg" /><figcaption>Image: <a href="http://ironmanhelmetshop.com/wanna-make-your-own-iron-man-helmet-hud/">http://ironmanhelmetshop.com/wanna-make-your-own-iron-man-helmet-hud/</a></figcaption></figure><p>We also see human + AI as an inspiration for current real-life neural interface work — as Jörn alludes to, the motivation behind Elon Musk’s founding of the BMI company <a href="https://waitbutwhy.com/2017/04/neuralink.html">Neuralink</a> can be stated as, “our best bet as a society of not being overtaken by a runaway artificial intelligence is to become a biological artificial intelligence ourselves.” Crazy, crazy, stuff. I’ll refrain from offering my opinion on the topic of the dangers of AI here, in part because I’m still developing it.</p><p>Human enhancement in general, of which human/AI fusion is a salient form, falls firmly within the bucket of “augmentation,” as I define it <a href="https://medium.com/the-substrate/on-the-human-substrate-and-how-we-can-change-it-85e6bb8ca7cb">here</a>. It requires fierce ethical rigor during its development and application, and I agree with Jörn in that these ethical considerations ought to be discussed by the public, and accessible to the public.</p><p>Have humans ever faced a similar scenario of choosing so overtly to change themselves? In a sense, we frequently elect to change ourselves in aesthetic domains: impermanently, we wear clothing, cut our hair, wear colored contact lenses; permanently, we receive tattoos and piercings.</p><p>Another method of changing ourselves is inventing and using technology. Illustrative anecdata: “life is so much different with smartphones” -any person who’s been alive for long enough to remember what life was like pre-smartphone.</p><p>More heavily, we can also consider the burgeoning field of <a href="https://ghr.nlm.nih.gov/primer/therapy/procedures">gene therapy</a>, in which diseases are treated or prevented by modifying our DNA. This field brings with it intense ethical questions, some of which are outlined <a href="https://ghr.nlm.nih.gov/primer/therapy/ethics">here</a>. As an interesting side-note, in his book <a href="https://www.amazon.com/Superintelligence-Dangers-Strategies-Nick-Bostrom/dp/1501227742">Superintelligence</a>, Nick Bostrom offers back-of-the-napkin calculations for the impact of orchestrating genetic selection for intelligence. Make no mistake, it’s a remarkably hairy topic.</p><p>With respect to aesthetics, general technological innovation, and even gene therapy: I would argue that the idea of plugging a computer into the brain and using this to incorporate artificial intelligence into subconscious or conscious processes is on a <em>whole different plane</em>. Why? Because we’d be <strong>controlling the substrate of human experience with precision</strong>, as opposed to <strong>grossly affecting the inputs to this substrate from the outside world</strong> (or, in the case of gene therapy, changing the genome that develops the substrate in an <a href="https://en.wikipedia.org/wiki/Epigenetics"><strong>environmentally-dependent way</strong></a>).</p><p>Given the weight of brain-based human enhancement, we clearly need this to be a topic discussed in the public forum; i.e., politically. I’m not sure yet how I think this can/ought to occur — I’m working on these thoughts, and would love to hear anyone’s suggestions. As part of my exploration on this front, I have some planned readings in neurophilosophy and neuroethics. Thoughts-in-progress:</p><ul><li>Without conferring any value judgement here, people will be <em>magnificently</em> resistant to brain-based augmentation. My dad, as a moderately change-resistant individual, doesn’t like getting new cellphones. I’ll let you know how it goes when I pitch him on a new brain.</li><li>The <a href="https://en.wikipedia.org/wiki/Naturalistic_fallacy">naturalistic fallacy</a>/<a href="https://en.wikipedia.org/wiki/Appeal_to_nature">appeal to nature</a> is going to show up. I’m not an expert, but this is basically the notion that “because nature created something this way, it ought to be this way.”</li><li>Security concerns are real. The collection of behavior data by companies like Facebook is already fiercely debated; brain data will be maybe an order of magnitude more polarizing (Jörn talks about this in the last quarter of the podcast episode).</li><li>Brain-computer interfaces that enable human/AI fusion will be extremely expensive. Which means they’ll initially be accessible only to those with money + power. Which means the powerful become more powerful…(Tony Stark, with his aforementioned Jarvis augmentation, is a fictional example I find intriguing).</li></ul><p>At some point down the road, as I coalesce perspectives on how to ethically and democratically introduce human augmentation through brain technologies, I’ll write an extensive post dedicated to the topic (although I won’t promise you when this will be, yet). Regardless, I’d be remiss not to offer the significant disclaimer that these questions are probably a decade (if not more) from reaching public prominence, and it would be an awful mistake to let them overshadow the incredible <a href="https://www.sciencedirect.com/science/article/pii/S0969996114003714">therapeutic benefits of brain computer interfaces</a> that the hard work of folks like Dr. Jörn Rickert and the CorTec team will bring to patients in the near future.</p><h3>In Conclusion</h3><p>In this post, I talked about the <a href="http://neuralimplantpodcast.com/">Neural Implant Podcast</a> interview with Dr. Jörn Rickert of CorTec, a company building a closed-loop implantable neural interface for therapeutic applications of human/AI fusion. Inspired by CorTec’s mission, I offered some nascent ruminations on the human/AI fusion.</p><p>One of my primary goals with The Substrate is to encourage an ethics-first conversation about brain-computer interfaces. To that end: comment, write me at <a href="/service/mailto:hello@thesubstrate.com">hello@thesubstrate.com</a>, or find me on <a href="https://twitter.com/averybedows">Twitter</a> (@averybedows). I will respond! (seriously, I will).</p><p>Until next time,</p><p>Avery</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fd38d9320e43" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-substrate/cortec-and-the-human-ai-fusion-fd38d9320e43">CorTec and the human/AI fusion</a> was originally published in <a href="https://medium.com/the-substrate">The Substrate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[On the human substrate, and how we can change it]]></title>
            <link>https://medium.com/the-substrate/on-the-human-substrate-and-how-we-can-change-it-85e6bb8ca7cb?source=rss-c7506c12d100------2</link>
            <guid isPermaLink="false">https://medium.com/p/85e6bb8ca7cb</guid>
            <category><![CDATA[neuroscience]]></category>
            <category><![CDATA[cognitive-science]]></category>
            <category><![CDATA[artificial-intelligence]]></category>
            <category><![CDATA[neurotechnology]]></category>
            <category><![CDATA[bioengineering]]></category>
            <dc:creator><![CDATA[Avery Bedows]]></dc:creator>
            <pubDate>Mon, 26 Feb 2018 22:59:03 GMT</pubDate>
            <atom:updated>2018-05-14T20:53:15.916Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*VfSp5MHEhpn07FRgvYxFyA.png" /></figure><blockquote>There’s lots of ways to be as a person, and some people express their deep appreciation in different ways.</blockquote><blockquote>But one of the ways that I believe people express their appreciation to the rest of humanity is to make something wonderful and put it out there.</blockquote><blockquote>But somehow, in the act of making something with a great deal of care and love, something is transmitted there. And it’s a way of expressing to the rest of our species our deep appreciation. So, we need to be true to who we are and remember what’s really important to us.</blockquote><p>-Steve Jobs, in the <a href="https://www.youtube.com/watch?v=KENk9AZNQzM&amp;t=80s">iPhone X launch video</a> (apologies for the triteness of using a Jobs quote, it’s just really damn good)</p><p>My “default mode” is to ruminate on the workings of my mind, the workings of the other minds around me, how I interact with those minds, and how they interact with each other. It’s not surprising, then, that I’ve recently fallen in love with neuroscience. I’ve been inhaling knowledge and theories deeply; I’ve been enjoying the taste of <a href="https://courses.lumenlearning.com/boundless-ap/chapter/motor-pathways/">motor pathways</a>, the scent of sensory <a href="https://en.wikipedia.org/wiki/Transduction_(physiology)">transduction</a> specializations, the coolness of <a href="https://en.wikipedia.org/wiki/Lateralization_of_brain_function">hemispheric lateralization</a>. In other words, I’ve been consuming.</p><p>But: I’ll inevitably leave this world one day, and <strong>my</strong> knowledge will go away. Whatever understanding I’ll have gained of people, how they work, and how they can lead positive lives — gone. This learning is, alone, a selfish pursuit…unless I use it for something other than my own satisfaction. A friend recently recounted to me advice offered by her dad:</p><blockquote>“You are what you produce, not what you consume.”</blockquote><p>I don’t think I could live with myself if I were to leave the world without first giving something to it (pardon the paradox). Something that outlasts me. Something that lets me say “hey, thanks, I appreciate you in a really profound way.” A contribution of the type alluded to by Steve Jobs.</p><p>I appreciate the world deeply. The people in my life are magnificent beyond what I can reasonably expect to convey with words (except by telling you that I can’t convey it with words). I’ve encountered art that makes me feel <em>real things</em> (see, for example, <a href="http://www.imdb.com/title/tt1065073/">Boyhood</a>). I go to a coffee shop that literally feels like a home. I have a new workout buddy, at long last.</p><p>And so I’m inspired by Jobs to ask myself: what do I want to give to the world? What do I want to make that outlasts me and therefore “express[es] to the rest of our species [my] deep appreciation?”</p><p>The answer I’ve come to is that I want to <strong><em>make it better to be a human</em></strong>. Our cultures, our societies, our nations — they all pour countless effort into this (hopefully…). Pursuing peace instead of war. Infrastructure. Food proliferation. Economic productivity. Entertainment. Art. Medicine. Most of the structures in our civilizations are dedicated to making the human experience better. Clearly, though, there’s still enormous suffering <a href="https://en.wikipedia.org/wiki/Hedonic_treadmill">innate</a> to being alive as a human being. To tremendously simplify, let’s say that the human brain consumes <strong>inputs</strong> from the world, and produces thoughts, feelings, and actions as <strong>outputs</strong>. These civilization structures all try to change inputs.</p><p>I don’t think it’s possible to eliminate innate suffering simply by changing the inputs…so, I have a hypothesis. My hypothesis is that in order to eliminate suffering, I ought to look to the substrate on which the human experience exists: the brain. Specifically, I need to interface with the brain — and hence, I look to the field of <strong>brain-computer interfaces</strong> as a way to produce something that outlasts me. I want to produce a change in the human experience that reduces suffering.</p><p>This piece you’re reading right now is the first in a publication I’m calling <em>The Substrate</em>, which is about brain-computer interfaces and how they can improve the experience of being a human.</p><h3><strong>Therapies vs. Augmentations</strong></h3><p>There are two broad approaches to improving the human experience with <a href="https://en.wikipedia.org/wiki/Brain%E2%80%93computer_interface">brain-computer interfaces</a> (BCI; a.k.a brain machine interfaces or BMIs; a.k.a neural implants).</p><p>The first approach is <strong>therapeutic</strong>. Millions of people have a quality of life which has been significantly reduced by nervous system damage—paralysis, inflammatory disease, stroke-induced loss of movement, blindness, etc. (I use “etc.” here in the gravest of ways). The frontier of BCIs is therapeutic: <a href="http://neuralimplantpodcast.com/dr-chad-bouton-on-teaching-paralysed-people-to-play-guitar-hero">returning movement to a paralyzed limb</a>, running a current through a nerve to <a href="https://setpointmedical.com/files/SetPoint_UEGW%20final_11x17in.pdf">reduce the symptoms of inflammatory disease</a>, helping a stroke victim <a href="https://jneuroengrehab.biomedcentral.com/articles/10.1186/s12984-017-0328-9">learn to move their arm again</a>, implanting a device into the retina to help <a href="http://www.secondsight.com/g-the-argus-ii-prosthesis-system-pf-en.html">stimulate cells that send visual signals to the brain</a>, and many more.</p><p>Much of the funding for BCI research, and much of the industry work to monetize these technologies, is necessarily focused on therapeutic applications of nervous system implants. If you’re interested in learning more, the <a href="http://neuralimplantpodcast.com/">Neural Implant Podcast</a> is an <em>incredible</em> resource (I’d know; I listened to ~30 of the podcast episodes over the span of a week, and I can happily report that I learned a lot).</p><p>The second approach to improving the human experience is <strong>augmentative</strong>. It’s an approach which aims to make humans into “superhumans” by plugging a device into their nervous systems (disclaimer: I detest the frivolity implied by “superhumans”, but the word is apt in the sense of “more than human”). For me, as someone who loves people and spending time around them, perhaps the most compelling type of augmentation would be technology that enables direct communication between brains. I find some of my most qualitatively human moments to be those spent engaging with other humans.</p><p>Therapeutic BCI will be funded sooner, and will mitigate more acute suffering, than augmentative BCI. Most of the work in the small but growing field is focused on helping people, and overlaps significantly with the world of medicine.</p><p>Augmentative BCI, on the other hand, feels uniquely human in that it allows us, with our intellect and imagination, to rethink the everyday experience of being a human in order to improve the baseline human experience. A herculean task, with profound ethical implications.</p><h3><strong>The goal of The Substrate, and my inspiration</strong></h3><p>I’m addicted to my Facebook News Feed. I mindlessly extract my phone from my pocket, let it scan my face, open Safari, go to <a href="http://facebook.com/">facebook.com</a> (I deleted the app), and start scrolling…all without any conscious awareness that I’m doing it. After a few flicks of my thumb, then I start to notice.</p><p>So what would happen if I could access Facebook posts simply by thinking? Or Snapchat stories that are neural virtual reality instead of iPhone videos? This seems like it could horribly exacerbate the addictive nature of platforms that provide human experience on demand.</p><p>This kind of social-media-meets-BCI—at least in principle — is feasible through the use of an implant that can both read from, and write to, neurons in the brain’s cortex (although it’s probably pretty far off). This is brain-brain communication, and it’s on a <a href="https://paradromics.com/niob/#niob-1">DARPA-funded</a> journey from science fiction to science reality—a journey that culminates with an open Pandora’s box filled with issues of privacy, addiction, human agency, human identity, and philosophy.</p><p>I contrast this dystopic vision with a vision I personally look forward to: the ability to communicate in polysensory, multimodal ways. The ability to communicate a visceral sensation, perhaps in addition to the words I use to describe it. Effective communication is one basis for the success of human civilization (and for me, a source of joy in life), and I think multimodal brain-brain communication could make us better communicators by leaps and bounds!</p><p>Therapeutic BCIs are the first step forward, and it’s hard to argue against their merits; augmentative BCIs come later, but despite potential positives—like multimodal communication—that bring humans closer, the potential for negatives like addictive human-experience-on-demand is strong as well.</p><p>If the designers of new human experiences are more attentive to institutional incentives (e.g. governmental or fiscal) than to human impact, then the potential for ultimately using BCI to make it more positive to be a human could go wildly astray.</p><p>It’s my goal, therefore, to use this publication to craft a conversation around brain technology that is pessimistically optimistic. That is: move forward with excitement, but be as careful as we can at every step.</p><h3>What you’ll find on The Substrate</h3><ul><li>I’ll write posts corresponding to the wonderful <a href="http://neuralimplantpodcast.com/">Neural Implant Podcast</a>: each of these posts will summarize the topic of each the episode, sometimes dive into the associated academic literature, and always offer some of my own thoughts.</li><li>As I learn more and more about brain-computer interfaces in academia and in industry, I’ll write about my corresponding theses/hypotheses. Disclaimer: these are my thoughts and mine alone, and they could easily change over time! I think it’s incredibly important for me to be transparent with my learning process, so I’ll acknowledge it when I turn out to be wrong, or if an opinion changes. Minimize authorial pride, maximize effective discourse.</li><li>Guest posts! Do you want to teach about something in particular? Do you want to make an argument for *insert your favorite method of interfacing with the brain*? I’d love to have you :) Just reach out at hello@thesubstrate.com.</li><li>Wild card…who knows!</li></ul><p>My hope is that together, through learning and conversation and imagination and ethical mindsets, we can humanely make it better to be a human…that we can humanely change The Substrate.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=85e6bb8ca7cb" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-substrate/on-the-human-substrate-and-how-we-can-change-it-85e6bb8ca7cb">On the human substrate, and how we can change it</a> was originally published in <a href="https://medium.com/the-substrate">The Substrate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>